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Abstract 
The present phase of stereotactic radiosurgery treatments started at IPOCFG in 
2008, after a modernization of the radiotherapy department. Till now, around 400 brain 
lesions were treated, the majority of which were brain metastases. 
Radiosurgery is a treatment modality where high doses of ionizing radiation are 
delivered in a single fraction with high accuracy to a small and well-defined intracranial 
target while minimizing the irradiation of the surrounding normal brain tissue.  
At IPOCFG, radiosurgery is performed using a linear accelerator equipped with 
a micro-multileaf collimator of Brainlab (m3 mMLC) and a dynamic conformal arc 
irradiation technique using 6 to 7 noncoplanar arcs centred at the isocenter which is 
located at the centre of mass of the lesion.  
The treatment procedure is completed in a single day, over a set of steps, carried 
out by a multidisciplinary team. My master's project focused on the treatment planning 
phase. The purposes were: 1) to configure the treatment parameters according to the 
tumour type and location in order to create plan templates that speed up and optimize 
the planning process; and 2) from the casuistic of the lesions treated at IPOCFG to 
evaluate if the acquisition of a 160 MLC with 5 mm leaf width at isocenter (MLC-160) 
would enable to dispense the use of the m3 mMLC without significantly compromising 
the quality of the clinical treatment plans.  
During treatment planning, the quality of a radiosurgery treatment plan is 
assessed through dose-volume indices that score the dose distribution in terms of 
coverage and conformity. To understand the treatment plan quality evaluation, a review 
and critical analysis of the dose-volume indices described in the literature was made, 
as a starting point of this project.  
Subsequently, specific templates for acoustic neurinoma and different 
metastatic lesions were established and evaluated in terms of plan quality. Applying the 
proposed specific templates the compliance to local plan acceptance quality criteria was 
achieved with adjustment of the mMLC shape for just two/three arcs used for treatment. 
This allowed a considerable reduction – to around 1/3 to 1/2 of the treatment planning 
time.  
Moreover, the casuistic of brain metastases treated at IPOCFG was reported and 
the outcome evaluated for 250 metastases in 168 patients treated between March 2008 
and December 2014. Median overall survival was 9 months from the date of the 
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treatment. Patient’s age and primary tumour location were identified as significant 
predictive factors for survival. Local control was achieved in 85.2% of the evaluated 
brain metastases and no significant factors were associated with the local tumour 
progression.  
Finally, the loss in terms of plan quality if the m3 mMLC was replaced on the 
linear accelerator by the MLC-160 was studied and it was demonstrated that the 
replacement would not represent a beneficial option. The main drawbacks would be 
less effective conformity and organ at risk sparing, mainly for irregular lesions and 
lesions located at close proximity of critical structures. 
 
Keywords: Stereotactic radiosurgery, treatment planning, plan quality, dose-volume 
indices, multileaf collimator, leaf width  
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Resumo 
A atual fase de tratamentos de radiocirurgia estereotáxica começou no IPOCFG 
em 2008, depois da modernização do serviço de radioterapia. Até ao momento, já foram 
tratadas mais de 400 lesões cerebrais, sendo a maioria metástases.  
A radiocirurgia estereotáxica é uma modalidade terapêutica em que altas doses 
de radiação ionizante são administradas numa única fração, a lesões intracranianas de 
pequenas dimensões e com limites bem definidos. Desta forma consegue-se atingir o 
volume a tratar, poupando os tecidos cerebrais sãos envolventes.  
No IPOCFG, a radiocirurgia é realizada usando um micro-colimador 
multifolhas da Brainlab (m3 mMLC), com completa integração num acelerador linear, 
em modo de fotões de 6 MV. A técnica de irradiação baseia-se na distribuição de dose 
por 6 a 7 arcos não coplanares convergentes no centro de massa da lesão (isocentro).  
Este tratamento é feito num único dia, integrando um conjunto de passos, 
levados a cabo por uma equipa multidisciplinar. O meu projeto de mestrado centrou-se 
na fase de planeamento do tratamento. Os objetivos foram: 1) configurar os parâmetros 
de tratamento de acordo com o tipo de tumor e a sua localização, no sentido de constituir 
planos-modelo para agilizar e optimizar o processo de planeamento; e 2) face à 
casuística de lesões tratadas no IPOCFG avaliar se a aquisição de um MLC de 160 
folhas com 5 mm de largura (MLC-160) permitiria dispensar o uso do m3 mMLC sem 
comprometer significativamente a qualidade dos planos clínicos.  
Durante a fase de planeamento do tratamento, a qualidade da distribuição de 
dose avalia-se através índices de dose-volume. Estes índices são uma ferramenta muito 
poderosa que facilita a tomada de decisões durante a comparação dosimétrica de vários 
planos. Por isso, começou por ser feita uma revisão bibliográfica e uma análise crítica 
dos índices de qualidade descritos na literatura.  
Subsequentemente, foram desenvolvidos planos-modelo específicos para o 
tratamento de casos clínicos de neurinoma do acústico e metástases cerebrais e avaliada 
a qualidade dos planos. A aplicação destes modelos e o ajuste da forma das folhas do 
m3 em 2 ou 3 arcos dos 6 a 7 usados no tratamento permitiu uma redução do tempo de 
planeamento em cerca de 1/2 - 1/3.  
Adicionalmente, foi feita uma análise da casuística de lesões metastáticas 
tratadas no IPOCFG, e avaliado o resultado do tratamento em termos de sobrevivência 
e controlo tumoral local. Entre Março de 2008 e Dezembro de 2014, foram tratados 168 
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doentes com um total de 250 metástases cerebrais. O tempo de sobrevida mediano 
estimado foi de 9 meses após a data de tratamento. A idade do doente e a localização 
do tumor primário foram identificados como fatores que afetam a sobrevivência. 
Quanto ao controlo local, 85.2% das metástases cerebrais avaliadas foram controladas 
ou desapareceram, sendo que não foram encontrados fatores associados com a 
progressão local do tumor.  
Por último, foi estudado em que medida é que a eventual substituição do m3 
pelo MLC-160, contribuiria ou não para a degradação da qualidade dos planos de 
tratamento. Foi demonstrado que a dispensa do m3 não representa uma boa opção. Os 
principais problemas associados a essa mudança residiriam na diminuição da 
conformidade da distribuição dose, bem como numa proteção menos efetiva das 
estruturas críticas, principalmente quando se consideram lesões irregulares ou próximas 
de órgãos de risco. 
 
Palavras-chave: Radiocirurgia estereotáxica, planeamento do tratamento, qualidade 
dos planos, índices dose-volume, colimador multifolhas, largura das folhas  
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1.1 | Radiosurgery at IPOCFG, E.P.E. 
Stereotactic radiosurgery (SRS) is a minimally invasive radiation treatment 
modality that delivers with high accuracy a large dose of ionizing radiation to a specific 
intracranial target, in a single fraction. The irradiation is based in multiple noncoplanar 
arcs of convergent x-rays beams.  
At IPOCFG, on the day of the SRS treatment a head ring is fixed to the patient’s 
skull under local anaesthesia. This provides a rigid fixation system that minimizes head 
motion and a frame of reference whereby the lesion location can be determined. After 
the immobilization, each patient undergoes two computed tomography (CT) scans – 
with and without contrast – on a dedicated big-bore CT simulator. A localization box 
is attached to the stereotactic head frame for imaging acquisition. The box includes 
tubes filled with a high-contrast material that provides easy to delineate fiducial marks. 
The fiducials provide a coordinate system that allows the precise determination of the 
position of the treatment volume with respect to the stereotactic head frame through the 
so called stereotactic transformation. Magnetic resonance (MR) images of the whole 
brain are also obtained for all patients, usually within a week before the treatment. Both 
CT and MR images are electronically transferred to the treatment planning system for 
co-registration. The neuroradiologist approves the fusion and delineates the structures, 
including the target lesion and the relevant organs at risk. The treatment plan is 
performed at the planning workstation and it is normally constituted by six or seven 
dynamic conformal arcs, almost always with a single isocenter per lesion. After the arcs 
configuration the dose distribution is computed using a pencil beam algorithm. Isodoses 
and further dose statistics are produced for plan evaluation.  
Every time a stereotactic treatment is to be delivered, an additional collimator 
must be attached to the linear accelerator (LINAC) head – a micro multileaf collimator 
(mMLC) – with a minimum leaf width of 3 mm (m3) which allows to achieve more 
precise beam delivery and better definition of small fields.  
Stereotactic radiosurgery demands extraordinary attention to quality assurance 
issues. This is related to the high accuracy required by the possible proximity of the 
target lesion to eloquent brain structures and to the high doses delivered. The quality 
control phase of the SRS treatment takes around one hour and precedes the treatment 
delivery. Finally, the patient is placed on the treatment couch, the target location is 
confirmed and the irradiation takes place.  
4 | Motivation and Goals  
 
 
Figure 1.1 summarizes the basic steps of a SRS treatment at IPOCFG. 
 
Figure 1.1 – The basic steps of a SRS treatment at IPOCFG. 
 
This project focuses on the treatment planning phase, where the irradiation 
strategy is designed in order to accomplish the treatment dose prescription. 
 
1.2 | Motivation and Goals  
At IPOCFG, the treatment planning uses a generic template (defined with 6 
dynamic arcs) just differing in position for right or left lesions with no adjustments for 
the tumour type or specific location of the lesion in the brain. For each specific clinical 
case, the plan optimization includes the need to determine the optimal arc properties. 
Subsequently, the conformity of the dose distribution to the target volume is 
accomplished through a time consuming process where for each arc the mMLC leaves 
are manually adjusted.  
The main goals of this project were twofold: i) first to configure the treatment 
parameters according to the tumour type and location in order to create templates that 
speed up and optimize the  treatment planning process; ii) from the casuistic of the 
lesions treated with SRS at IPOCFG to evaluate the quality loss if the micro-multileaf 
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collimator (minimum leaf width of 3 mm) used for SRS was replaced by an integrated 
multileaf collimator with 160 leafs (5 mm leaf width) on the linear accelerator.  
1.3 | Organization of the Dissertation  
This dissertation results from the compilation of a set of self-consistent papers, 
written in English, all with an underling thread on optimizing procedures in stereotactic 
radiosurgery.  The five resulting papers have been written along the 10 months of the 
MSc. project carried out at the Medical Physics Department of IPOCFG:  
 
I. Dose-volume Quality Indices for Radiosurgery Treatment Plan Assessment: 
A review. (Submitted to Acta Radiológica Portuguesa)  
II. Definition and evaluation of a template to speed up radiosurgery treatment 
planning of acoustic neurinoma. ( Electronic Poster presentation at the 3rd 
ESTRO Forum, 24-28 April 2015, Barcelona, Spain)  
III. Stereotactic Radiosurgery for the treatment of brain metastases: definition 
and evaluation of templates to speed up treatment planning. (Manuscript) 
IV. Stereotactic Radiosurgery of brain metastases: analysis of outcome. 
(Submitted to Acta Neurochirurgica)  
V. Dosimetric comparison of multileaf collimator systems for intracranial stereotactic 
radiosurgery (Submitted to Physica Medica)  
 
The self-consistency of each paper implied some redundancy mainly in the 
introductory paragraphs that could not be avoided. 
 
The quality of radiosurgery treatment plans is assessed through the calculation 
of dose-volume indices. These indices are a complementary and powerful tool that 
facilitate decisions during the dosimetric comparison of various treatment plans. The 
definition of these indices progressed over the last decades as demonstrated by the 
number of papers that can be found in the literature. In order to summarize the quality 
indices defined for radiosurgery treatment plan assessment, a comprehensive review 
was made – Paper I (Chapter 2).  
To get used with the treatment planning system while aiming at following the 
first objective of the project, specific templates for right and left acoustic neurinomas 
were developed and evaluated in terms of plan quality –  Paper II (Chapter 3).  
6 | Organization of the Dissertation  
 
 
A retrospective planning study was also made to develop specific templates with 
adjustments for different metastatic lesions locations, to evaluate their quality and to 
determine the minimum number of arcs where the mMLC shape must be adjusted for 
the treatment plans to comply with the local acceptability criteria. For the latter task, a 
simple brain mapping has been considered and a user-friendly graphical interface was 
developed in order to assist the planner in choosing the adequate specific template – 
Paper III (Chapter 4).  
The casuistic study of all brain metastases treated at IPOCFG from March 2008 
to December 2014 and a treatment outcome evaluation, identifying the factors that may 
influence the overall survival and the local control were made. These analyses have 
been slightly off the main objectives of this project, however, they gave me a clear idea 
about the patients and the characteristics of the treated lesions as well as an evaluation 
of the outcome associated with this treatment technique and a comparison with the 
results reported by other institutions. Moreover they have allowed me an interesting 
and useful contact with some biostatistics methods and tools – Paper IV (Chapter 5).  
Finally, the quantitative evaluation, in terms of plan quality losses, of the 
eventual replacement of the 3 mm micro MLC by a 160 MLC with 5 mm leaf width 
was carried out as a support study to that management decision – Paper V (Chapter 6).  
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Abstract 
Dose-volume quality indices measure the homogeneity of the dose distribution, 
the coverage of the target by the prescription isodose surface and the conformity of the 
prescription isodose to the target volume. The definition of these indices progressed 
over time being the conformity indices those that evolved the most. They became highly 
sophisticated evolving from just volumetric definitions to definitions that take into 
account the organs at risk affectation, the size and shape of the target volume or the 
dose gradient outside the target volume.  
The search for such useful tools has been continuous along the last decades as 
demonstrated by the number of papers that can be found in the literature concerning 
this issue.  A comprehensive review on the quality indices defined for radiosurgery 
treatments assessment is presented. 
 
2.1 | Introduction 
Stereotactic radiosurgery (SRS) is a minimally invasive treatment technique 
where high doses of radiation are delivered in a single fraction with high accuracy to a 
small and well-defined target. Targets are commonly small intracranial lesions [1]. 
SRS combines the principles of stereotaxy (from Greek: “stereo” – three-
dimensional space, “taxy” – localization) for localization of target volume with multiple 
collimated beams of focused high energy photon radiation. This creates a steep dose 
gradient in the borders of the target that allows a selective damage of tumours and a 
maximum protection of healthy tissues [1,2].  
Because SRS is a highly focused treatment, it is useful in situations where the 
tumour is small (the larger dimension shall not exceed 3 cm) and contained into a 
localized area [2].  Malign tumours (metastatic brain tumours, gliomas, ependymomas, 
medulloblastomas), benign tumours (neurinomas, meningiomas, pituitary tumours) and 
non tumour pathologies such as arteriovenous malformations are indicated for SRS 
treatment. Also, SRS may be used as a complementary treatment in case of residual 
lesions, recurrent small sized lesions of the brain or as a local “boost” at the end of the 
conventional external beam radiation therapy [1,2]. 
 
10 | Introduction 
 
 
 
2.1.1 | Evolution of Radiosurgery  
Horsely and Clark [3] were the first to create an apparatus for defining brain 
locations with Cartesian coordinates, in 1908. In 1951 the Swedish neurosurgeon 
Leksell introduced the Radiosurgery concept [4]. 
There are three basic forms of SRS represented by three different technological 
instruments: Gamma Knife, Linear accelerator (LINAC) and systems that accelerate 
heavy particles as protons (cyclotrons or synchrotrons). 
In the late 1960’s, Leksell and Larsson [5] developed a system named Gamma 
Knife. This system was constituted by 179 sources of Cobalt-60 and the gamma 
radiation was focused in a target stereotaxically localized.  Gamma Knife systems 
suffered multiple modifications over the years and systems with 201 sources are 
presently the most used.  
LINAC-based radiosurgery systems were first proposed by Betti and 
Derechinsky [6] in 1984 and a year after by Colombo et al. [7]. Betti and Derechinsky’s 
system used circular collimators of different diameters coupled to the linear accelerator 
and the SRS treatment was achieved with multiple convergent and noncoplanar arcs. 
Since then, linear accelerator-based SRS has become highly sophisticated, evolving 
from circular arc and multiple isocenters per target to dynamic conformal arcs usually 
based on a single isocenter. 
The dynamic conformal arc irradiation technique uses a micro-multileaf 
collimator (mMLC) to conform the radiation beam to the target volume every 10 
degrees. The capacity of continuous dynamic movement of the leaves and the 
continuous conformation to the target volume during irradiation, allow improving the 
conformity and homogeneity of the dose distribution in irregular targets [8].  
In 1962, at the Massachusetts General Hospital in Boston, Kjelleberg [9] 
presented a proton beam-based radiosurgery system. This system used protons of 150 
MeV produced by a synchrotron. Proton beams deposit more energy as they slow down, 
culminating in an absorption peak (the Bragg peak). This allows the majority of the 
radiation dose to be delivered to the target site and significantly reduce the dose to 
normal tissues near the target. 
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2.1.2 | Radiosurgery Treatment Assessment  
For evaluating a treatment plan the visual inspection of the dose distribution 
image by image still is one of the most important and used methods. Another helpful 
tool for evaluating plan quality and compare competing plans are dose-volume-
histograms. Dose-volume-histograms summarize the dose and volume statistics for 
delineated structures and give information on the volume of a given structure that 
receives a particular dose. However, when comparing different plans, dose-volume-
histograms may contain large amounts of data which make the comparison difficult and 
time consuming. So, multiple plans of treatment can more easily be compared through 
the use of quality indices. Probably the most cited parameters to classify radiosurgery 
treatment plans are the so called indices of conformity and coverage [10]. Indices of 
this type were defined for the first time in 1993 by the Radiation Therapy Oncology 
Group (RTOG) [11]. 
 
2.2 | Dose-volume quality indices: definitions and 
discussion 
2.2.1 | Coverage Indices 
RTOG in 1993 [11] was the first to propose a coverage index defined as a ratio 
between doses: 
 
Coverage (RTOG)  =  TC =
𝐷𝑚𝑖𝑛
𝑝𝑖
 2.1 
 
where Dmin is the minimum dose in the target volume and pi is the prescribed isodose 
value. TC stands for Target Coverage. 
A value of TC equal to 1.0 corresponds to an ideal coverage (the target volume 
completely covered by the prescription isodose surface); when the value is between 
0.9-1 the treatment plan is considered to comply with the protocol; when TC is in the 
range 0.8-0.9 the protocol violation is considered to be minor, and if TC is below 0.8 
the protocol violation is considered to be major. 
If the target volume is located adjacent to a critical organ which has normally a 
tolerance dose lower than the therapeutic dose for the tumour, for protecting the critical 
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organ it may be necessary to underdose a small volume of the target. In this case, the 
minimum dose in the target may be low in a small volume, but coverage may be 
acceptable which is not taken into account in the coverage index defined by RTOG 
[10]. 
Lomax and Scheib in 2003 [10] presented a new definition of coverage that 
solved this problem. That new coverage index definition is a relation between volumes: 
 
TC (%)  =  
𝑉𝑇,𝑝𝑖
𝑉𝑇
×  100% 2.2 
 
where VT,pi is the volume of target that receives at least the prescription dose and VT is 
the target volume as shown in Figure 2.1. 
 
 
Figure 2.1 – Definition of the volumes used in dose-volume quality indices. The solid line shows the 
target volume, VT; the dotted line shows the prescription isodose, pi; represented in grey is the volume 
within the target receiving at least the prescription isodose, VT,pi. 
 
Ideally, TC will be 100%. The aim is a TC ≥ 95%, but the acceptable coverage 
depends on the clinical indication and on the position of the target thus while for a 
benign lesion a coverage between 90%–95% may be acceptable, for the treatment of 
metastases, the coverage should be close to 100%. 
2.2.2 | Homogeneity Indices 
RTOG in 1993 [11] defined an index, Homogeneity Index (HI) or Maximum 
Dose to Prescribed Dose (MDPD) that helps to evaluate the homogeneity of the dose 
distribution: 
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HI (MDPD)  =  
Dmax
pi
 2.3 
 
where Dmax is the maximum dose in the target volume and pi is the prescribed isodose 
value. MDPD should be less than 2.0. If this occurs, the treatment plan is considered to 
comply with the protocol. When this index is between 2-2.5 there is a minor protocol 
violation, and when it is above 2.5 the protocol violation is considered to be major, 
though the plan might still be considered as acceptable. 
2.2.3 | Conformity Indices 
Several different conformity indices have been proposed to describe the 
conformity of the prescription isodose to the target volume. PITV ratio, proposed by 
RTOG in 1993 [11] is defined as the total volume enclosed by the prescription isodose 
divided by the target volume: 
 
PITV =  
𝑉𝑝𝑖
𝑉𝑇
 2.4 
 
where Vpi is the volume of the prescribed isodose and VT is the target volume as shown 
in Figure 2.1. A value of 1.0 would indicate a perfect conformation. A value between 
1 and 2 indicates that the plan is considered to comply with the protocol; 2 ≤PITV≤2.5 
or 0.9≤PITV≤1.0 indicate a minor deviation, and PITV≤0.9 or PITV≥2.5 would 
correspond to a major deviation. 
Nedzi et al. in 1993 [12] used a conformity index called Treatment Volume 
Ratio (TVR) which was defined as the ratio of the target volume to the treatment 
volume (volume of prescription isodose). This index is the inverse of PITV. Knöös et 
al. in 1998 [13] proposed the Radiation Conformity Index (RCI) that is again the inverse 
of PITV.  
A Conformity index was also defined in the ICRU 62 Report [14] in 1999 from 
previous RTOG recommendations. In this definition it was imposed that “the planning 
target volume (PTV) is fully enclosed by the treated volume (reference isodose 
volume)”. This means that 100% coverage is assumed and there, the conformity index 
is defined as the ratio between the treated volume (reference isodose volume) and the 
planning target volume (target volume). 
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These conformity indices are simply a ratio between volumes and do not 
consider the location or shape of the prescription isodose relatively to the target volume. 
So, a perfect conformity score could eventually be obtained with a prescription isodose 
surface not at all, or only partly, overlapping the target volume, contributing to a 
significant dose to normal tissues [10].  
In 1997, Van’t Riet et al. [15] presented the Conformation Number (CN). This 
index basically combines two ratios: the proportion of the target covered by the 
prescription isodose (equivalent to TC) and the proportion of the prescription isodose 
volume that covers the target, as follows: 
 
CN =  
𝑉𝑇,𝑝𝑖
𝑉𝑇
 ×  
𝑉𝑇,𝑝𝑖
𝑉𝑝𝑖
 2.5 
 
where CN is the conformation number, having a value between 0 and 1. When CN is 1 
the conformation is ideal. Van’t Riet et al. suggested that plans may be considered 
conformal if they have a CN greater than 0.6. 
In 1998, the definition of CN was renamed as COIN (Conformity Index) by 
Baltas et al. [16]. COIN is the product between the CN and a factor that takes into 
account the dose received by critical organs. So, when there are no critical organs near 
the target volume, COIN is equal to CN and can be written as: 
 
COIN =
[𝑉𝑇,𝑝𝑖]
2
𝑉𝑝𝑖𝑉𝑇
 2.6 
 
When there are critical organs near the target volume, COIN will be named 
COIN’ taking into account the degradation of its value: 
 
COIN’ =  COIN ∏ [1- 
𝑉𝐶𝑂𝑟𝑒𝑓
𝑖
𝑉𝐶𝑂
]
𝑁
𝑖=1
 2.7 
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The product factors are defined for each critical organ i, where VCOref is the 
volume of the critical organ (CO) that receives at least the prescription dose and VCO 
the volume of that critical organ. 
However, COIN’ only refers to the fractional volume of critical organ receiving 
the prescription dose or higher which deserves two important remarks. The first is that 
it mixes information about target coverage, normal tissue irradiation and specific 
critical organs, and it is impossible to distinguish the contribution of each term to the 
resultant COIN’ value. The second is that COIN’ only accounts for critical organ 
volumes receiving prescription doses and higher. In many cases, critical organ 
tolerances are lower than tumour prescription doses and this is not considered about 
this restriction [17]. 
Paddick in 2000 [18] proposed a conformity index (CIP)  that is basically equal 
to CN and in 2001 it was modified by Nakumura et al. [19] and presented as the inverse 
of the initial index (CIN).  
Lomax and Scheib in 2003 [10] suggested a Conformity Index (CI) that solved 
the PITV problem of geographic miss. This new index was defined as the ratio of the 
volume of target receiving at least the prescription dose, to the volume enclosed by the 
prescription isodose. 
 
CI =  
𝑉𝑇,𝑝𝑖
𝑉𝑝𝑖
 2.8 
 
CI scores the normal tissue overdose, however, it does not contain complete 
information about the target coverage, and different quality plans can have identical CI 
values. For example, if the prescription isodose is completely enclosed in the target 
volume, the CI score will be 1 although the plan would not obviously be ideal (See case 
3, Table 2.1) [10].  
COIN, CN and CI should be greater than 0.6 for the plan to be consider 
conformal [10,15,16]. 
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Table 2.1 – Summary of coverage and conformity indices for various treatment plans, enhancing the 
results obtained for the different index definitions. (Adapted from [10]) 
Treatment 
Plan /Case 
Volumes 
(cm3) 
TC(%)[10] PITV[11] RCI[13] 
CN=COIN= 
CIP[15,16,18] 
CIN[19] CI[10] 
1 
 
VT=2.0 
Vpi=4.0 
VT,pi =2.0 
100% 2.0 0.5 0.5 2.0 0.5 
2 
 
VT = 2.0 
Vpi=2.6 
VT,pi =1.8 
90% 1.3 0.77 0.62 1.27 0.69 
3 
 
VT =2.0 
Vpi=1.0 
VT,pi=1.0 
50% 0.5 2.0 0.5 1.0 1.0 
4 
 
VT = 2.0 
Vpi=2.0 
VT,pi =1.0 
50% 1.0 1.0 0.25 4.0 0.5 
 
Table 2.1 shows four simplified treatment plans and summarizes the different 
proposed dose-volume indices. In Case 1 the target volume is completely enclosed in 
the prescription isodose surface and so, the target coverage is perfect. However, there 
is a poor conformity as shown by all conformity scores (CN, CI, PITV, RCI, CIN). In 
Case 2 the prescription isodose surface is slightly shifted towards the left of the target 
volume, therefore the target coverage is worse than in Case 1, but the conformity is 
much better because a less amount of healthy tissue receives the prescription dose.  In 
Case 3 the prescription isodose is completely enclosed in the target volume which will 
give a perfect CI score although the poor conformity of the isodose shape relatively to 
the target volume enhances the failure of this definitions. Indeed if CI is used alone it 
will be misleading because it does not contain complete information about the target 
coverage. On the other hand, CN index includes a target coverage factor which is 
accounted by the low score. In Case 4, the target volume and the volume of the 
prescribed isodose are equal but slightly apart and therefore PITV is 1 in spite of 
conformity is not clearly good. This reflects the PITV geographic miss but, CN and CI 
overcome this PITV problem and show the lack of conformity. 
A study made by Wu et al. [20] demonstrated that currently used conformity 
measures, namely the PITV, would provide misleading results of the quality of a 
treatment plan when examining small target sizes or complex shapes. PITV tends to 
have higher values for smaller or more complex targets even when the prescription 
isodose coverage is equivalent to other plans for larger volumes or simpler shapes. 
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To overcome this limitation, the authors Wu et al. [20], proposed a Distance-
based Conformity Index (CDI) that is independent of the target size and shape and in 
which the conformity of the prescription isodose to the target volume is measured as 
the average distance between the surfaces of the target and the prescription isodose, as 
follows: 
 
CDI =
(𝑉𝑝𝑖−𝑉𝑇,𝑝𝑖)+(𝑉𝑇−𝑉𝑇,𝑝𝑖)
1
2
×(𝑆𝑇+𝑆𝑝𝑖)
      2.9 
 
where ST is the surface of target and Spi the surface of prescription isodose. For 
calculating the target and prescription isodose surfaces, Wu et al. approximated the 
target and prescription isodose volumes to ellipsoids. For each target, they measured 
the major axes to get the elongation ratio and then calculated the volume. However, if 
the volume has a very irregular shape this approximation will not be good. 
An important feature of radiosurgery is the steep dose gradient outside the target 
volume. An index that gives a measure of the dose falloff outside the target – 
Conformity/Gradient Index (CGI) – was proposed by Wagner et al. [21] in 2003. The 
CGI was defined as the average of two terms, a conformity score (CGIc) and a gradient 
score (CGIg) given as follows: 
 
CGIc = 100 ×
VT
Vpi
 2.10 
 
CGIg =  100 – {100 ·  [(𝑅𝐸𝑓𝑓,50%𝑝𝑖 − 𝑅𝐸𝑓𝑓,𝑝𝑖) –  0.3 cm]} 2.11 
 
where REff, pi is the effective radius of the prescription isodose volume and REff,50%pi is 
the effective radius of the 50% isodose volume.  
The effective radius of a volume is the radius of a sphere of equal volume, and 
is calculated as: 
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𝑅𝐸𝑓𝑓 = √
3V
4π
 
3
 2.12 
 
The final CGI index value is given by: 
 
CGI =  (CGIc +  CGIg)/2 2.13 
 
A CGIg ≥ 100 corresponds to an optimum 3 mm or steeper gradient (distance 
between the prescription and the 50% isodoses effective radii). This ideal 3 mm 
gradient was obtained empirically from radiosurgery planning cases, and corresponds 
to the gradient that is possible with LINAC radiosurgery when using multiple 
noncoplanar arcs and small circular collimators (<20 mm) [21].  
CGIg score scales linearly with differences in effective dose shell radii, for 
example, when CGIg = 90 the effective gradient is 4 mm, when CGIg is 80 the effective 
gradient is 5 mm, and so forth. 
The CGI increases with plan desirability or quality, such that an ideal plan with 
CGIc = 100 and CGIg = 100 would have a CGI score of 100. As either the conformity 
or the gradient worsens, CGIc or CGIg decreases, and the CGI score therefore decreases 
[21]. 
However, the CGI does not address the issue of dose homogeneity within the 
target volume. CGI also does not consider the radiation dose to radiosensitive structures 
other than non-target brain tissue. Maximizing CGI score allows minimizing the 
quantity of healthy tissue that receives high doses (≥ 50% of the prescription dose). So, 
the probability of not having treatment complications is maximized but just when all of 
the non-target volume is of about the same radiosensivity. When there are different 
radiosensivities (highly or less radiosensitive structures) near the target volume, CGI 
does not provide information about doses to these radiosensitive structures [21].  
In 2006, Paddick [22] proposed another index to evaluate the steep dose gradient 
outside the target volume – Gradient Index (GI). The GI is defined as the ratio of the 
volume of the 50% isodose to the volume of the prescription isodose: 
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GI =
𝑉50%𝑝𝑖
𝑉𝑝𝑖
 2.14 
 
This index can be used to compare treatment plans of equal conformity but with 
different dose gradients. A smaller value of GI reflects a steeper dose gradient and, 
therefore, a lower irradiation of healthy tissues. This is particularly useful in critical 
anatomical locations or larger volumes where the GI helps to select the dose plan with 
the lowest “penumbra dose” and particularly important for multi-isocenter treatments, 
which are used in the majority of Gama Knife dose plans [22]. 
In 2006, Menhel et al. [17] proposed a new index that allows distinguishing 
between different critical organs, Critical Organ Scoring Index (COSI). This new index 
considers the target coverage and critical organ irradiation: 
 
COSI =  1 −
𝑉(𝐶𝑂)>𝑡𝑜𝑙
𝑇𝐶𝑉
 2.15 
 
where V (CO)>tol is the fraction of volume of the critical organ (CO) receiving more 
than its tolerance dose, and TCV is the volumetric target coverage, defined as the 
fractional volume of target volume covered by the prescription isodose. 
COSI yields a false perfect score if the critical organ is completely spared, 
regardless of tumour coverage. When COSI is < 1 it is impossible to know if this is due 
to a poor target coverage or to an overdosage of the critical organ. This loss of 
information is actually present in any of the conformity indices that account for more 
than one factor, either coverage and conformity or for multiple organs [17].   
To overcome these problems and facilitate the choice of an optimal treatment 
plan, the same authors, proposed a two-dimensional representation of COSI versus 
Conformity Index (CI), where CI is the index proposed by Lomax and Scheib (Eq.8).  
The combination of CI and COSI compensates both for the loss of information 
contained in the definition of COSI and CI when each is used separately, and for the 
potential false perfect scores that COSI yields. Thus, if COSI = 1 due to a complete 
organ sparing, but the target coverage is poor, this will be reflected in a low CI value 
[17]. The advantage of a two dimensional representation is demonstrated in Figure 2.2. 
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In Figure 2.2 a hypothetical case of three different plans is presented, with one target 
volume and one CO to be assessed. 
 
 
Figure 2.2 – COSI vs CI for three different plans and one critical organ. Each plan is a point in the 
plane. The Perfect plan scores at COSI=CI=1. (Adapted from [17]). 
 
The ‘+’ denotes an ideal plan, with a perfect target coverage, perfect conformity 
and full critical organ sparing. Plan 1 is the best in terms of conformity (conformity 
index of 0.95). Plan 2 is the best in terms of critical organ sparing. Plan 1 and Plan 3 
have the same COSI but they may not spare the critical organ on the same amount. 
Through the analysis of CI and TC definitions (CI = VT,pi/Vpi and TC=VT,pi/VT), it is 
possible to express  CI as  
𝑇𝐶×𝑉𝑇
𝑉𝑝𝑖
. As Figure 2.2 shows, CI of Plan 1 is greater than CI 
of Plan 3, and this can be due to a greater target coverage or to a smaller prescription 
isodose volume. If the target coverage of Plan 1 is greater than the target coverage of 
Plan 3, for COSI in the two plans to be the same, the fraction of critical organ in Plan 
1 that receives more than its tolerance dose should be greater than that fraction in Plan 
3 and so, the critical organ in Plan 1 is less spared than in Plan 3.  
In case of Plan 2, CI is lower than in Plans 1 and 3 but COSI is higher.  As CI 
and COSI are 0.85 and 0.95 the target coverage is necessary high although lower than 
in the other plans and so, the organ sparing should be the best of all three plans.  
All three plans have acceptable CI and COSI values, so the choice will probably 
depend on what type of critical organ is being assessed and whether organ sparing is 
more important than target conformity or vice versa.  
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Table 2.2 summarize the discussed dose-volume indices. 
 
Table 2.2 – Summary of the dose-volume indices. 
 
Other approaches for evaluating treatment plans that were not discussed here 
are Normal Tissue Complication Probability (NTCP), Tumour Control Probability 
(TCP) and more recently Equivalent Uniform Dose (EUD). The advantage of this type 
of indicators over the purely dosimetric dose-volume indices is that they attempt to 
incorporate radiobiology, and thus they are more intuitively related to the treatment 
outcome but they are out of the scope of the present paper [17]. 
 
2.3 | Conclusion 
Indices for evaluating the quality of a radiosurgery plan can facilitate decisions 
during the dosimetric comparison of various treatment plans. They allow choosing the 
plan that provides the best compromise in terms of coverage, conformity and 
homogeneity because multiple parameters can be easily analysed. Dose-volume indices 
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allow not only the evaluation of the quality of the different treatment plans, but also 
facilitate the comparison between various available techniques and technologies, 
because these influence the geometry of the dose distributions.  
The ideal solution to the problem of plan evaluation would be an index that 
could both integrate all the relevant data and present it in a simple and quantitative 
form, but unfortunately such ideal tool does not exist. Namely because the treatment 
plan evaluation will always be a multiple criteria problem. As it has been discussed, 
each previous definition includes some drawbacks that may hide out some important 
features of the dose distribution either concerning the target or the healthy surrounding 
structures.  
In order to harmonize definitions and also to save planning time, it would be 
important that the treatment planning systems could include some of the needed tools 
to calculate these indices. Such implementation would enable the users to choose the 
suitable quality indices and include them in the approved plan documentation along 
with the details of the dose calculations, tending to comply with reporting level 3 
according to ICRU 83 recommendations [23]. 
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Abstract 
Purpose: A Generic Template with no specific adjustments for tumour type is used at 
IPOCFG for linear accelerator-based radiosurgery treatment planning. It involves 
further manual adjustments of the micro-multileaf collimator (mMLC) leaves in all the 
generic arcs for improving the treatment plan quality which is a cumbersome task. The 
purpose of this work is to present specific templates for right and left acoustic 
neurinomas and compare their performance with the Generic Template in terms of plan 
quality, and to determine the minimum number of arcs where the mMLC shape must 
be adjusted for the treatment plan to comply with the local acceptability criteria.  
Methods and Materials: The treatment plans of twelve cases of right acoustic 
neurinomas treated at IPOCFG were analysed. From this retrospective study, a Specific 
Template for right acoustic neurinoma was created and the Specific Template for left 
acoustic neurinoma was defined as precisely the mirror of the right template. In total, 
nineteen cases involving acoustic neurinomas have been re-planed with the Specific 
Template (right or left) and their plan quality assessed. Treatment planning was 
conducted using the iPlan RT Dose planning system, version 4.5 from BrainLAB. The 
target volumes ranged from 0.265-7.523 cm3 (mean: 2.085±1.772 cm3) and the 
prescribed dose was 12-14 Gy (mean: 12.15±0.50 Gy). Treatment plans were generated 
using 6 dynamic conformal arcs and their quality evaluation was assessed through the 
calculation of dose-volume indices and dose distribution analysis.  
Results: The Specific Template performed better than the Generic Template in terms 
of conformity (COIN=0.558±0.034 for the Specific Template and COIN=0.547±0.034 
for the Generic Template) and critical organ sparing (COIN’=0.554±0.031 for the 
Specific Template and COIN’=0.538±0.031 for the Generic Template). The coverage 
and the homogeneity of the dose distribution were similar for both: TC=0.981±0.007, 
MDPD=1.065±0.013 for the Specific Template and TC=0.984±0.007, 
MDPD=1.067±0.013 for the Generic Template.  
Conclusion: Applying the proposed Specific Template for acoustic neurinoma, the 
compliance to local acceptance quality criteria was achieved with manual correction of 
the mMLC leaves for just two of the six dynamic arcs used for treatment. This 
represented a considerable reduction – to around 1/3 – of the treatment planning time, 
accomplishing the purpose of the present work which was speeding up the treatment 
planning phase in radiosurgery without jeopardizing the plan quality. 
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3.1 | Introduction  
Acoustic neurinomas (vestibular schwannomas) are benign and slow-growing 
tumours that develop in the myelin sheath of the vestibular branch of the VIII cranial 
nerve. As the tumour grows, it expands from its origin inside the internal auditory canal 
out into the space between the brainstem and the temporal bone known as the 
cerebellopontine angle. The pear-shaped tumour can continually enlarge, compressing 
the trigeminal nerve and can eventually compress the brainstem. Acoustic neurinomas 
represent approximately 10% of all brain tumours, they are slightly more common in 
women and appear at an average age of 50 years old. Symptoms include unilateral 
sensorineural hearing loss of variable degrees, instability, vertigo, tinnitus, headache 
and even facial numbness [1,2]. 
The cause of acoustic neurinoma is largely unknown. They can be sporadic (in 
95% of the time) or caused by an inherited condition called neurofibromatosis type 2. 
Neurofibromatosis type 2 origin acoustic tumours in both left and right sides – bilateral 
acoustic tumours [1]. 
As acoustic neurinomas are benign and slow growing tumours an immediate 
treatment may not be necessary if patient has few symptoms. The option to observe 
every year these tumours until they grow or symptoms change is a possible approach 
[2]. 
Historically, treatment options have included total or subtotal surgical tumour 
resection that evolved for micro-surgical methods. For healthy patients with 
symptomatic unilateral tumours, surgical resection has been considered the standard 
treatment. However, some patients are elderly or medically infirm (patients that have a 
tumour in the only ear, bilateral acoustic neurinomas, post-surgical recurrence) and 
others reject surgery. Furthermore, the location of these tumours at the skull base in 
close proximity to multiple critical neurological structures (cranial nerves, brainstem) 
leads to appreciable surgical morbidity. Presently a well-established alternative to 
surgical resection in the case of small and medium-sized acoustic neurinomas (< 3cm) 
is stereotactic radiosurgery (SRS). This technique ensures an acceptable control rate 
and low rate of neuro-otological complications. Conventional radiotherapy is not used 
in acoustic neurinoma treatment, although there exists some evidence of its efficacy 
[2]. 
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The aims of radiosurgery and surgery are different. Surgery aims at totally 
remove the tumour while radiosurgery intention is to stop the tumour growing by 
inducing avascular necrosis leading to collagen deposits [2,3]. 
The first radiosurgical treatment of an acoustic neurinoma was proposed in 1969 
and was carried out in 1971 [3].  
At IPOCFG, the radiosurgery treatment of neurinomas is linear accelerator 
(LINAC)-based. The technique is based in dynamic conformal arcs (DCA) rotating 
about a single isocenter using a micro-multileaf collimator (m3 mMLC) to conform to 
the target volume. 
The treatment planning uses a Generic Template (just defined as right or left 6 
arc template) with no specific adjustments for neurinomas and so, for each clinical 
situation, the physicist needs to determine which arc properties are the optimal. This is 
a non-trivial problem, especially because the brainstem is anatomically close to the 
target. Additionally, the conformity of the dose distributions is further accomplished 
through a time consuming process where for each arc the mMLC leaves are manually 
adjusted for each sub-incidence, every 10 degrees.  
The aims of this work were to develop and evaluate in terms of plan quality a 
Specific Template for cases of acoustic neurinoma (right and left) with optimized arc 
parameters and prescription details, as well as to determine the minimum number of 
arcs where the mMLC shape must be adjusted for the treatment plan to comply with 
the local acceptability criteria. 
 
3.2 | Methods and Materials  
3.2.1 | Target Lesions 
Clinical records of 19 patients with acoustic neurinoma that underwent SRS 
between 23 January, 2013 and 21 May, 2014 formed the basis of this retrospective 
study. These 19 patients have in total 12 right-sided lesions, 6 left-sided lesions and 1 
bilateral lesions ranging in volume from 0.265 to 7.523 cm3 (mean: 2.085±1.772 cm3). 
The dose prescribed to the planning target volume (PTV) ranged from 12 to 14 Gy 
(mean: 12.15±0.50 Gy). 
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3.2.2 | Organ at Risk 
Acoustic neurinomas grow and expand from their origin to the space between 
the brainstem, therefore in the radiosurgery treatment planning the brainstem is 
considered as the important organ at risk (see Figure 3.1). 
 
 
Figure 3.1 – Planning target volume (in red) and Brainstem representation (in green) in a magnetic 
resonance imaging (MRI) slice. 
 
From QUANTEC (Quantitative Analysis of Normal Tissue Effects in the 
Clinic) compilation, Sharma et al. in 2008 [4] reported that exposing the brainstem to 
more than 12 Gy produces new neurological deficits. Mayo et al. in 2010 [5] suggested 
that a maximum brainstem dose of 12.5 Gy is associated with low (<5%) risk. 
At IPOCFG 12 Gy is considered the brainstem’s tolerance dose. 
3.2.3 | Treatment Technique  
SRS is performed using the mMLC of BrainLab, with full advanced integration 
in a Siemens Oncor Avant-Garde linear accelerator using the 6 MV photon mode. The 
mMLC has 26 pairs of leafs: from centre to periphery, 14 pairs have 3 mm width, 6 
pairs have 4.5 mm width and 6 pairs have 5.5 mm width – Figure 3.2. It is a tertiary or 
additional collimator which must be attached to the LINAC head every time a 
stereotactic treatment is to be delivered – Figure 3.3. 
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Figure 3.2 – m3 mMLC collimation system. Courtesy Brainlab. 
 
 
Figure 3.3 – LINAC-based radiosurgery system. Courtesy Brainlab. 
 
The irradiation technique is based on 6 or 7 dynamic conformal arcs, always 
with a single isocenter for each lesion.  
During irradiation, the gantry is rotating while the leaves of the mMLC move 
according to the beam’s eye view (each leaf of the mMLC moves linearly at 10° 
intervals interpolating from the initial position to the next calculated position). The 
capacity of continuous dynamic movement of the leaves and the continuous 
conformation to the target volume during the irradiation, allow improving the 
conformity and the homogeneity of the dose distribution for irregular targets. 
3.2.4 | Treatment planning 
Treatment planning is conducted using computed tomography (CT), contrast-
enhanced magnetic resonance (MR) images and the iPlan RT Dose planning system, 
version 4.5 from BrainLAB.  
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MR images are fused with planning CT images using iPlan RT Image version 
4.1.1 (BrainLAB). Then, the neuroradiologist approves the image fusion and delineates 
the gross tumour volume (GTV) and the brainstem on the MR images. Subsequently, 
the planning target volume (PTV) is defined as the GTV plus an isotropic margin of 
1mm incorporating the clinical target volume (CTV) and accounting for setup errors 
and other possible isocenter localizing uncertainties. 
The treatment plan is normally constituted by 6 dynamic conformal arcs defined 
by the parameters: table position, gantry start, gantry stop, collimator angle, weight and 
margin as Figure 3.4 shows. The treatment planning software creates a field shape using 
the m3 that conforms to the outline of the PTV plus a predefined margin of 3mm in the 
beam’s eye view in the starting position of the arc and for every 10° sub-arcs. 
 
 
Figure 3.4 – Irradiation Plan Tab of the iPlan RT Dose 4.5 Irradiation plan. On the left, the Dyn Arc 6 
is highlighted in blue and below all the corresponding parameters are displayed. 
 
Figure 3.4 shows the Irradiation Plan Tab in iPlan. The upper left view, the 
collision map, shows a two-dimensional view of the segmented objects as projected 
onto a spherical surface: brainstem localization in green and the arcs representation in 
blue. The isocenter is positioned at the centre of the view. The beam eye view (upper 
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right view) shows the GTV (orange contour), the PTV (red contour), the brainstem 
(green contour), and the m3 leaves of arc 6 in 160 degrees gantry position are 
represented.  
The shapes of the defined arcs concentric at the PTV (in red) are shown in the 
three-dimensional (3D) overview (lower left view). The slice view (lower right view) 
displays the brainstem contour (in green) and the PTV and GTV in red and orange, 
respectively. 
On the bottom left of every view, an icon indicates the orientation of the patient 
position. The orientation of the patient icon helps to verify from what angle the four 
views display the respective object. The view orientation in the 3D views is displayed 
in accordance with the position of the gantry and table. The table/gantry icon in the 
bottom right of the collision map indicates the positions of the gantry and the treatment 
table.  
To define a treatment plan the Functions and the Prescription tabs are used [6]. 
a) Functions Area 
The Functions tab shows different buttons and spin boxes.  
Table, Gantry and Collimator spin boxes allow changing the numeric value of 
the treatment table angle or the starting and stopping points of the gantry in an arc.  
The margin spin box allows to assign a margin (in millimetres) to the PTV 
geometrical conformation by the mMLC leaves for an individual arc. In order to 
achieve the required dose falloff and to compensate for the penumbra region, a 
sufficient margin should be given. Normally a 2–3 mm mMLC margin is added around 
the PTV. 
The weighting spin box allows to define the weighting (in percentage) for each 
arc. Weighting determines the percentage of the dose that the arc delivers to the PTV, 
and thus the number of monitor units (MU) calculated for the respective arc [6].   
The treatment plan usually includes six dynamic conformal arcs: two dynamic 
conformal arcs on the opposite side of the lesion, three in the same side of it and one 
corresponding to a cranial incidence as Figure 3.4 presents.  
b) Prescription Area 
The treatment prescription is generically defined by the number of treatment 
fractions (1 fraction in the case of SRS), the prescription dose (in Gy) and the 
34 | Methods and Materials 
 
 
 
restrictions that are imposed to limit the dose to the organs at risk (OAR) and other 
normal tissues. Figure 3.5 shows the Prescription Dialog window. 
 
 
 
Figure 3.5 – Prescription dialog of the Generic Template. 
 
To the left side of the Prescription dialog window the Objects list is presented 
containing all visible objects. To the right of this list, there is an Object Type options 
area. Here an object is defined as either PTV, Boost, OAR Type 1, OAR Type 2, OAR 
Type 3 or Other object. OAR type 1 provides the maximum protection for the respective 
organ at risk, whereas OAR type 3 does not have an influence on the leaf adaptation, 
but provides the dose-volume-histogram (DVH) constraint information on the 
respective object in the DVH dialog. If an object is defined as OAR type 2, the system 
Definition and evaluation of a template to speed up SRS treatment planning of acoustic neurinoma | 35 
 
 
evaluates the respective location with respect to the PTV during leaf optimization. The 
result can be, for example, that small parts of the PTV margin are covered by a leaf in 
order to protect the corresponding area of the OAR.  
To the right of the Object Type list, there is the graph area that displays the DVH 
of the object highlighted in the Objects list.  
Bellow the graph, there is a Numeric button that opens the Adjust dialog 
window where the dose-volume constraints can be defined.  Bellow the Object Type 
options area, the percentage of the dose for a particular volume, the number of fractions 
and the prescribed dose are defined. The dose display options are valid for the entire 
treatment plan [6].  
In the Generic right or left Templates – Figure 3.5, the brainstem is not 
considered as an organ at risk. Their prescription just defines the tumour as a PTV and 
imposes that 97.6% of the PTV should receive the prescription dose. 
3.2.5 | Treatment plan Evaluation  
The treatment plan quality evaluation is accomplished through the calculation 
of dose-volume indices, the visual inspection of the dose distribution image by image 
and the analysis of the DVHs for the different structures, namely the minimum dose in 
the PTV (DMin(PTV)), the maximum dose in the brainstem (DMax(BS)) and the volume of 
the brainstem that receives more than its tolerance dose (this volume is named as V12 
Gy(BS)). 
The dose-volume indices assess the homogeneity of the dose distribution – 
MDPD (ratio between maximum dose and the prescribed dose) [7] – the coverage of 
the target by the prescription isodose surface – TC (target coverage) [8] – and the 
conformity of the prescription isodose to the target volume – PITV (ratio of the 
prescription isodose surface volume to the target volume) [7] and COIN (conformity 
index) [9]. They have been reviewed in a former paper [10]. 
For a treatment plan to be acceptable, it must meet the criteria shown in Table 
3.1. 
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Table 3.1 – Plan quality acceptability criteria. 
Parameter Value 
TC ≥ 95% 
COIN ≥ 0.6 
PITV ≥1 & ≤ 2 
MDPD ≥1 & ≤ 2 
DMin(PTV) ≥ 95% × Prescribed Dose 
DMax(BS) ≤ 12 Gy 
V12Gy(BS) (cm3) as low as possible and 
usually <<0.1 cc 
 
3.2.6 | Specific Template Creation  
Through the retrospective analysis of the approved treatment plans for all 
patients with right neurinoma, a right template with six dynamic conformal arcs was 
created. Template definitions are shown in Table 3.2. The left template (for left 
neurinomas) was defined afterwards with precisely the mirrored values for table 
position, collimator position, gantry start and gantry stop. The prescription is the same 
for the two templates. 
 
Table 3.2 – Properties of the six dynamic conformal arcs for the right neurinoma Specific Template. 
Table Gantry Start Gantry Stop Collimator Weigthing 
10 230 350 320 18.6% 
37 220 340 320 16.5% 
64 210 340 300 13.4% 
90 200 340 270 10.3% 
300 150 20 60 19.6% 
335 140 10 45 21.6% 
 
The Specific Template prescription defines the tumour as a PTV and the 
brainstem as an organ at risk type 3. PTV’s dose-volume constraints impose that 97.6% 
of the volume must receive the prescription dose and that the maximum dose must be 
less than 107% of the prescribed dose. In the dose-volume constraints of the brainstem 
12 Gy is considered the tolerance dose.  
To improve the conformity between the target volume and the prescription 
isodose and so sparing healthy tissues and protecting the brainstem, manual 
adjustments still have to be made in the mMLC shape. In the Generic Template these 
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adjustments are made in all the arcs which is a very time consuming task. Arcs 
weighting determines the dose percentage that each beam delivers to the PTV. The most 
heavy arcs impact significantly the dose distribution and so, for speeding up the 
radiosurgery treatment planning, after the Specific Template application, the mMLC 
leaves were adjusted just in the heaviest arcs, arc 1, arcs 1 and 6 and arcs 1, 6 and 5, 
and the plans quality were successively assessed.  
The treatment plan quality was evaluated through the use of the same methods 
referred in page 35. Critical Organ Scoring Index (COSI) proposed by Menhel et al. 
[11] and COIN’ which is a derivation of COIN that takes into account the degradation 
of its value when there are critical organs near the target volume were also calculated. 
These indices evaluate the brainstem sparing.  For a plan to be considered conformal 
both indices should be greater than 0.6. 
 
3.3 | Results and Discussion 
A comparison between the Specific Template and the Generic Template was 
made to demonstrate the advantages in terms of plan quality of using the Specific 
Template instead of the Generic Template and so, to validate its development. The two 
templates were independently applied and the direct plan quality provided by each one 
was assessed with no adjustments made in the mMLC shape. 
In Figure 3.6, COIN index average values reflect that the Specific Template 
provides a better conformity than the Generic Template, on average, for the studied 
clinical cases and the COIN’ index average values indicate that the Specific Template 
is better in terms of critical organ sparing, as expected because the Generic Template 
does not consider the brainstem as an organ at risk. Although the Generic Template 
ignores the presence of the brainstem, the templates difference in terms of organ at risk 
sparing is not large because the prescription dose and the brainstem tolerance dose are 
both equal to 12 Gy. 
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Figure 3.6 – COIN and COIN’ for Specific Template and Generic Template. 
 
The target coverage (TC) and the dose distribution homogeneity (MDPD) are 
similar for both as Table 3.3 shows. 
 
Table 3.3 – TC and MDPD indices for Specific and Generic Template. 
Index Specific Template Generic Template 
TC 0.981±0.007 0.984±0.007 
MDPD 1.065±0.013 1.067±0.013 
 
The treatment plans achieved with the Specific Template, for the studied clinical 
cases, can be divided into three groups according to the lesion localization that lead to 
similar quality indices in each group. Group 1 includes lesions that compress the 
brainstem (minimum distance between the brainstem and the lesion is 0 mm) and that 
have volumes larger than 3.5 cm3. Group 2 includes lesions that are far from the 
brainstem (the brainstem and the lesion minimum distance is between 1.5 mm and 15.2 
mm) but that have irregular shapes. Lesions that are very close (minimum distance less 
than 1.0 mm) or compress the brainstem and that have volumes smaller than 2.7 cm3 
belong to Group 3. To illustrate the group’s characteristics three cases randomly 
selected from each group are presented in Figure 3.7. 
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a)  
 
b)   c)  
Figure 3.7 a), b) and c) – Representation of the cases 1, 2 and 3 belonging to Group 1, 2 and 3, 
respectively. The 12 Gy isodose is represented in orange. 
 
 
Table 3.4 shows the Specific Template evaluation for these three cases. Indices 
that accomplish the criteria are shown in green, otherwise they are in red. 
 
Table 3.4 – Specific Template quality indices for 3 cases belonging to each of the 3 anatomic groups of 
neurinomas. 
 
In Case 1 target coverage, conformity and homogeneity are in concordance with 
the plan acceptability criteria presented in the Table 3.1, but the maximum dose in the 
brainstem is greater than its tolerance dose (12 Gy) due the lesion localization. In this 
case, the mMLC leaves adjustment will improve the brainstem protection. In Case 2, 
COIN indicates that conformity is poor due to the form of the lesion, but the maximum 
dose received by the brainstem is lower than its tolerance dose because the neurinoma 
is sufficiently away from this organ at risk. The adjustment of mMLC leaves, mainly 
reducing the template margin will improve the conformity quality. In Case 3 besides 
Case TC MDPD PITV COIN COIN’ COSI 
Dmin(PTV) 
(Gy) 
Dmáx(BS) 
(Gy) 
VBS(>12Gy) 
(cm3) 
1 0.981 1.070 1.565 0.615 0.592 0.963 11.540 12.520 0.375 
2 0.979 1.074 1.700 0.563 0.563 1.000 11.550 6.60 0.000 
3 0.988 1.078 1.738 0.562 0.550 0.979 11.58 12.600 0.169 
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the poor conformity, the maximum dose in the brainstem and the volume that receives 
at least 12 Gy are high, therefore the mMLC leaves adaptation will also improve the 
plan quality. 
After the Specific Template application the mMLC leaves were adjusted in the 
heaviest arcs: successively arc 1, arcs 1 and 6 and arcs 1, 6 and 5.  
With mMLC adjustments in arc 1 the conformity increases and the fraction of 
brainstem that receives at least 12 Gy decreases. However, COIN and COIN’ for Case 
2 still do not comply with the plan acceptability criteria. The compliance was achieved 
with manual correction of the mMLC leaves in arcs 1 and 6. Adjustments in these arcs 
improved conformity, homogeneity and organ sparing but the target coverage slightly 
decreased –Table 3.5. 
 
Table 3.5 – Evaluation of the Specific Template plus mMLC adjustment in arcs 1 and 6. 
 
Corrections in arcs 1, 5 and 6, further enhances the plan quality for the three 
cases. To understand if  the improving of quality indices with increasing the number of 
arcs where the mMLC is manually adjusted is actually a trend, the average value of 
each dose-volume index was calculated and presented in Table 3.6, for successive 
manual adjustments in arc 1, arcs 1 and 6 and arcs 1, 5 and 6. 
 
Table 3.6 – Average dose-volume indices values for all 19 cases of acoustic neurinoma, applying the 
Specific Template and with further adjustments in arc1, arcs 1 and 6 and arcs 1, 5 and 6. 
 
As it is shown in the table, the direct application of the Specific Template yields 
treatment plans that comply on average with the plan acceptability criteria in terms of 
Case TC MDPD PITV COIN COIN’ COSI 
Dmin(PTV) 
(Gy) 
Dmáx(BS) 
(Gy) 
VBS(>12Gy) 
(cm3) 
1 0.974 1.071 1.267 0.750 0.735 0.980 11.540 12.390 0.193 
2 0.982 1.072 1.547 0.623 0.623 1.000 11.560 6.660 0.000 
3 0.981 1.073 1.409 0.683 0.675 0.989 11.550 12.480 0.092 
 TC MDPD PITV COIN COIN’ COSI 
Specific 
Template 
0.981±0.007 1.065±0.013 1.732±0.558 0.558±0.034 0.554±0.031 0.992±0.011 
+ adj. in Arc 1 0.981±0.006 1.064±0.012 1.574±0.134 0.615±0.047 0.611±0.044 0.993±0.010 
+ adj. in Arcs 
1,6 
0.979±0.006 1.063±0.012 1.464±0.101 0.658±0.044 0.654±0.041 0.995±0.007 
+ adj. in Arcs 
1,6,5 
0.979±0.006 1.062±0.012 1.430±0.093 0.672±0.043 0.667±0.041 0.995±0.007 
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coverage and homogeneity. However, the conformity is poor as COIN and PITV 
reflect.  
The adjustment of the mMLC shape is clearly useful for improving the 
conformity. The mMLC adjustment in arc 1 allows, on average, an increase of 10% in 
COIN and a decrease of 9% in PITV (the ideal PITV value is 1) leading to COIN values 
that comply with the plan acceptability criteria. The mMLC adjustment in arcs 1 and 6 
improves in 18% the COIN and in 15% the PITV and the adjustment in arcs 1, 5 and 6 
increases COIN in 20.4% and decreases PITV in 17.4%, on average. COIN’ values 
show a substantial increase of the brainstem sparing with mMLC adjustments. As the 
brainstem tolerance dose and the prescribed dose are equal for acoustic neurinomas, the 
COSI index does not have any advantage relatively to COIN’ in this study. The critical 
organ affectation, if it exists, is so low that the COSI is always close to 1. However, 
COSI definition advantages are evident in other clinical cases as for instance in pituitary 
adenomas (see Appendix). 
The target coverage (TC) tends to decrease with the increasing of the number 
of arcs where the mMLC shape is adjusted, which is expected as the adjustment tends 
to cover regions where the PTV and the brainstem are close or adjacent. The 
homogeneity of the dose distribution given by the index MDPD is not significantly 
affected by the mMLC adjustments and can even slightly improve with it. 
The manual adjustment of the mMLC shape is a cumbersome task that slows 
down the treatment planning phase in radiosurgery. Therefore knowing the minimum 
number of arcs on which the mMLC shape adjustment may produce an acceptable plan 
is a very significant and useful information. The presented results show a strong 
evidence that the correction of the mMLC shape in just arcs 1 and 6, which are usually 
the ones with the higher weights, leads to treatment plans that comply with the 
acceptability plan criteria. To further corroborate this conclusion, Figure 3.8 presents 
the dose-volume indices corresponding to the Specific Template plus adjustment of the 
mMLC in arcs 1 and 6 – named Optimized Plans – versus the same indices for the 
Approved Plans with corrections in all arcs. 
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a)  b) 
c) d)  
Figure 3.8 a), b), c), d) – TC (%), MDPD, PITV and COIN’ of the Optimized Plans vs Approved Plans. 
 
Dashed lines have a slope equal to 1, so they represent equivalent results for 
both plans. If the points are above the dashed line for the TC and COIN’ representation 
and bellow the dashed line for the PITV and MDPD representations, the Optimized 
Plan with just two adjusted arcs and having the Specific Template as a starting point is 
better than the Approved Plan. All points below the dashed line for the TC and COIN’ 
representation and above the dashed line for the MDPD  and PITV representation are 
cases where the Optimized Plan could not achieve the Approved Plan quality.  
Figure 3.8 a), b), c), d) confirm that the correction of the mMLC shape in just 
two arcs produce treatment plans that in general respect the plan acceptability criteria. 
In 8/19 cases the target coverage (TC) of the Optimized Plan is equal or greater than 
the target coverage of the Approved Plan and it is always greater than 95% (the 
minimum acceptable value). In terms of conformity, in 14/19 cases COIN’ of the 
Optimized Plan is equal or greater than COIN’ of the Approved Plan and the PITV of 
the Optimized Plan is less than the PITV of the Approved Plan in 11/19 cases. MDPD 
is better in the Optimized Plan in 14/19 cases. PITV and MDPD are always less than 
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2.0 and therefore plans are acceptable according to these indices. COIN’ should be 
greater than 0.6 but in four of the Approved Plans it is less than this limit. Nevertheless 
this occurs in just one Optimized treatment Plan.  
To summarize the comparison between Approved and Optimized Plans, the 
average values of the dose-volume quality indices, minimum dose in the PTV and 
maximum dose in the brainstem were calculated and presented in Table 3.7.  
 
Table 3.7 – Average values of the dose-volume quality indices, minimum dose in the PTV and 
maximum dose in the brainstem for Approved treatment Plans and Optimized treatment Plans. 
 Approved Treatment Plan Optimized Treatment Plan 
TC 0.98±0.01 0.98±0.01 
MDPD 1.07±0.01 1.06±0.01 
PITV 1.49±0.01 1.46±0.10 
COIN 0.65±0.04 0.66±0.04 
COIN’ 0.64±0.04 0.65±0.04 
COSI 1.00±0.01 1.00±0.01 
Dmin(PTV) 11.80±0.50 Gy 11.79±0.50 Gy 
Dmax(BS) 10.11±3.47 Gy 10.35±3.44 Gy 
 
On average, for equal coverage, Optimized Plans are more homogeneous and 
conformal at the expenses of a slightly non-significant underdosage of the PTV 
(minimum dose of 1 cGy less) and a slightly overdosage of the brainstem (maximum 
dose of 24 cGy more) without exceeding its tolerance dose. 
 
3.4 | Conclusions 
The Generic Template standardly used at IPOCFG in the treatment planning of 
acoustic neurinomas treated with radiosurgery does not have specific adjustments for 
the tumour type and when it is applied, the optimization of the treatment plan to reach 
the acceptance criteria according to the local treatment protocol is a hard and time 
consuming task. The proposed specific templates (right or left) for acoustic neurinoma 
define the brainstem as an organ at risk and allow to have a better conformity just from 
the starting point. These represent a great advantage in terms of improving and speeding 
up the radiosurgery treatment planning phase.  
The Specific Template application with further adjustment of the mMLC leaves 
conformation in just two arcs, arcs 1 and 6, allows obtaining a treatment plan quality 
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that respect the plan acceptability criteria and in some cases with better indices than the 
approved treatment plans where the mMLC shape is adjusted in all arcs. This 
optimization reduces to around 1/3 the treatment planning time and so, the purpose of 
this work was fully accomplished. 
 
3.5 | Appendix: COIN’ vs COSI for pituitary adenomas 
Pituitary adenomas are relatively common brain tumours, representing 10-20% 
of all primary intracranial tumours [12]. Microsurgery and fractionated radiotherapy 
are historically the eligible treatment modalities but it has been demonstrated that 
radiosurgery offers a viable treatment for recurrent or residual pituitary adenomas [12].  
Between December 2012 and December 2014, 8 pituitary adenomas were 
treated with SRS at IPOCFG. The mean prescribed dose for these lesions was 16.3±1.5 
Gy. Optical nerves, brainstem and chiasm were considered as organs at risk in treatment 
planning due to their proximity to adenomas location – Figure 3.9. The corresponding 
tolerance doses are presented in Table 3.8.  
 
 
Figure 3.9 – Representation of a pituitary adenoma in red, brainstem in green and optic nerves right 
and left in yellow. 
 
 
Table 3.8 – Critical organs and corresponding tolerance doses considered at IPOCFG for SRS. 
Critical Organ Tolerance Dose (Gy) 
Brainstem 12 
Chiasm 8 
Optic Nerves 9 
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COIN’ definition considers the volume of each critical organ that receives at 
least the prescription dose but mixes information about target coverage, normal tissue 
irradiation and specific critical organs, being thus impossible to distinguish the 
contribution of each factor (see Chapter 2, page 19). Otherwise, COSI is calculated for 
each critical organ considering the volume of each critical organ that receives more 
than its tolerance dose. Figure 3.10 presents the COIN, COIN’ and COSI (C=Chiasm; 
BS=brainstem; RON=right optical nerve and LON=left optical nerve) values for three 
different treated cases, to illustrate the use of COSI. 
 
 
Figure 3.10 – COIN, COIN’ and COSI (for each critical organ) values. 
 
COIN and COIN’ values for the presented clinical cases of pituitary adenomas 
are equal for each of the three cases, indicating that the critical organs have been mostly 
spared. Nevertheless the sparing linked to COIN’ concerns just prescribed doses which 
in the cases of adenomas may be considerably higher than the tolerance dose of the 
proximal critical organs.  Indeed COSI values reveal how effectively the different 
organs at risk have been affected. In Case 1 and Case 3 the right optic nerve and the 
brainstem are mostly spared whereas for these two cases the chiasm was the organ at 
risk with the lowest dose protection, which derives from being the organ with the lowest 
tolerance dose. Concerning the left optic nerve, it is completely spared in Case 2 
whereas for Case 3 it is clearly affected in some extension. Overall, for these three 
examples of adenomas, we can say that Case 2 is the one with better sparing of the four 
considered organs at risk. 
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Organs at risk affectation depends of the clinical situation as for example the 
lesion volume, prescribed dose and lesion location. Table 3.9 presents the COIN, 
COIN’ and COSI average values for all clinical cases. 
 
Table 3.9 – COIN, COIN’ and COSI average values for approved adenoma treatment plans. 
COIN COIN’ COSI(C) COSI(BS) COSI(RON) COSI(LON) 
0.593±0.077 0.593±0.077 0.888±0.129 0.999±0.001 0.989±0.014 0.976±0.040 
 
COSI average values reflect that chiasm is the organ at risk mostly affected, as 
illustrated for the three clinical cases previously presented. Table 3.9 presents average 
values, but in a given clinical case, different treatment plans can be compared on the 
basis of the calculated values of COSI for each critical organ to help the physician’s 
decision on the best plan for treatment.  
In the clinical cases of pituitary adenomas COSI definition advantages have thus 
been demonstrated which was not so obvious for the previous described case of 
neurinomas. 
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Abstract 
Purpose: At IPOCFG, a generic template with no specific adjustments for tumour type 
neither for its brain location is used for linear accelerator based radiosurgery treatment 
planning. The purpose of this retrospective planning study was to present specific 
templates with adjustments for different metastatic lesions locations, compare their 
performance with the generic template in terms of plan quality and to determine the 
minimum number of arcs where the micro-multileaf collimator (mMLC) shape must be 
adjusted for the treatment plan to comply with the local acceptability criteria.  
Methods and Materials: From this retrospective study, a plain brain mapping was 
considered and a specific template developed for each defined brain region (15 in total). 
Cases involving brain metastases treated from October 2012 to August 2014 have been 
re-planed with the appropriate specific template and their plan quality assessed through 
the calculation of dose-volume indices and dose distribution analysis. Due to the high 
number of specific templates created, a user-friendly graphical interface was developed 
to help the specific template choice. Treatment planning was conducted using the iPlan 
RT Dose planning system, version 4.5 from BrainLAB. 
Results: The specific templates provide, at the starting point, better conformity and 
homogeneity of the dose distribution than the generic template (COIN=0.561±0.040 
and PITV=1.725±0.129 for the generic template and COIN=0.564±0.039 and 
PITV=1.716±0.132 for the specific templates). Target coverage is similar for both: 
TC=0.978±0.003 for the generic template and TC=0.978±0.004 for the specific 
templates. 
Conclusion: Specific templates for brain metastases allow to achieve treatment plans 
compliance with the local plan acceptability criteria with manual correction of the 
mMLC leaves for just three arcs of the 6/7 dynamic arcs used for treatment. This 
contributes for a reduction of the treatment planning time to around 1/2-1/3 without 
compromising the plan quality. 
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4.1 | Introduction  
Brain metastases smaller than 3cm in diameter represent the most common 
indication for stereotactic radiosurgery (SRS) [1]. SRS delivers a high dose of radiation 
to precisely defined intracranial lesions in a single fraction, using multiple convergent 
beams usually describing multiple dynamic concentric arcs. This contributes to a high 
and uniform dose to the target volume while minimizing the irradiation of the 
surrounding normal tissue which allows the treatment of brain metastases in any 
location, including inside the brainstem [1].  
Several randomized trials reported that SRS extends overall survival and 
accomplishes highly effective and predictable local control, for single and multiple 
brain metastases even for radioresistant metastases from melanoma or renal cancer [2-
4].  
The treatment planning uses a generic template (defined with 6 dynamic arcs) 
just differing in position for right or left lesions with no adjustments for the specific 
location of the lesion in the brain. For each specific clinical case, the plan optimization 
includes the need to determine the optimal arc properties. Due to the diversity of 
possible locations of brain metastases as they can appear in any brain location, even in 
close proximity to critical structures as brainstem and optic chiasm, this is not a simple 
task. The conformity of the dose distributions is further accomplished through a time 
consuming process where for each arc the mMLC leaves are manually adjusted for each 
sub-incidence, every 10 degrees.  
The purpose of this work was to create a specific template for each defined brain 
region, to evaluate its quality and to determine the minimum number of arcs where the 
mMLC shape must be adjusted for the treatment plan to comply with the local 
acceptability criteria. For the latter task, a simple brain mapping has been considered 
and a displaying tool was developed in order to assist the planner in choosing the 
adequate specific template. 
4.2 | Methods and Materials  
4.2.1 | Target Lesions 
A retrospective analysis of the treatment plans of 81 patients with brain 
metastases that underwent SRS between October 2012 and August 2014 was 
performed. These patients had in total 116 brain metastases ranging in volume from 
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0.13 to 19.94 (mean: 3.82±4.02 cm3). The prescribed dose average to the planning 
target volume (PTV) was 19.80±2.17 Gy (range: 12-24 Gy). 
4.2.2 | Treatment technique and treatment planning  
Radiosurgery treatment of brain metastases at IPOCFG is linear accelerator 
(LINAC)-based. The LINAC is a Siemens Oncor Avant Garde equipped with a tertiary 
collimator, a BrainLAB mMLC of 3 mm minimum leaf width. The irradiation 
technique is based on 6 or 7 dynamic conformal arcs, almost always with a single 
isocenter per lesion where the mMLC leaves adapt to the lesion geometry according to 
the beam’s eye view and so, further improve the conformity and homogeneity of the 
dose distribution.  
Treatment planning is conducted using computed tomography (CT) and 
contrast-enhanced magnetic resonance (MR) images obtained using a T1 SE (spin-
echo) sequence with Gadolinium contrast agent with no gantry tilt and a 1.0 mm 
thickness slices, fusion to assist structure delineation and the iPlan RT Dose treatment 
planning system, version 4.5 from BrainLAB [5].  
4.2.3 | Brain mapping 
Usually, the whole brain is divided in the main brain lobes shown in Figure 4.1.  
 
 
Figure 4.1 – Brain lobes. From [6].  
 
Based on this division, axial, coronal and sagittal slices of the brain CT images 
were analysed and divided in some broad regions. Sagittal slices were divided in 
frontal, temporal, parietal, occipital and cerebellar lobes; coronal slices were divided in 
superior, inferior and central regions and axial slices were divided in anterior, posterior 
as well as in right, left and central sides – Table 4.1.  
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Table 4.1 – Regions defined in each brain plane. 
SAGITTAL CORONAL AXIAL AXIAL 
Frontal Central Anterior Right 
Temporal Superior Posterior Left 
Parietal Inferior Central Central 
Occipital    
Cerebellar    
 
Figure 4.2 presents the pre-defined plain brain mapping, in each view. In Figure 
4.2 a) the considered frontal, parietal, temporal, occipital and cerebellar lobes are 
shown. Figure 4.2 b) shows the superior, inferior and central regions while Figure 4.2 
c) shows the anterior, posterior and central considered regions. 
 
 
 
Figure 4.2 a), b) and c) – Sagittal, coronal and axial views. 
 
Each brain metastases was assigned to a location referring to its position in 
coronal, sagittal and axial slices and grouped accordingly.  
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4.2.4 | Specific template creation 
Through the retrospective analysis of the approved treatment plans for patients 
with brain metastases, a specific template was created for each geographic 
localization/brain region defined. In total, 13 right and 2 central specific templates have 
been created. The left templates were defined as precisely the mirrored of right specific 
templates.  
Due to the high number of specific templates created, the quick selection of the 
most appropriate for each clinical situation could be an awkward task. So, a user-
friendly graphical interface was developed using MATLAB version R2014a – Figure 
4.3. The user just needs to point to the approximate position of the centre of the lesion 
in a coronal, sagittal or axial slice. After pointing to the lesion’s centre in a slice of a 
specific view, the three coordinates are automatically defined so, it is possible to 
completely characterize the geographic localization and to see the projection of the 
chosen point in the other slice views.  
 
  
Figure 4.3 – User interface overview. 
 
The specific template designation corresponds to ‘Metastase-’ plus the four 
initials of the geographic localization.  
As referred, 15 templates with specific parameters for each location have been 
created and their acronyms are presented in Table 4.2.  
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Table 4.2 – List of treatment templates created grouped by brain lobe location. 
Frontal Parietal Temporal Occipital Cerebellar 
FSAR/L PSPR/L TICR/L OCPR/L CIPR/L 
FCAR/L PSCR/L TCCR/L OSPR/L CICR/L 
 PCCR/L TCAR/L OCCR/L  
 
Parietal specific templates were defined with 7 dynamic arcs while temporal, 
occipital, frontal and cerebellar specific templates have 6 arcs. The left templates were 
defined with mirrored values of corresponding right templates for table and collimator 
positions, gantry start and gantry stop.  
Prescription details of all created specific templates are the same. The 
prescription defines the tumour plus 1 mm margin as a PTV and PTV’s dose-volume 
constraints impose that 97.6% of the volume must receive the prescription dose and 
that the maximum dose must be less than 107% of the prescribed dose.  
A comparison between the specific template created for each lesion localization 
and the generic template was made to demonstrate the advantages in terms of plan 
quality of using the specific template instead of the generic template and so, validate 
its development. The templates were independently applied and the direct plan quality 
provided by each one was assessed with no adjustments made for the mMLC shape.  
To improve the conformity between the target volume and the prescription 
isodose and so sparing healthy tissues and protecting the critical organs (for some brain 
metastases locations), manual adjustments still had to be made in the mMLC shape. In 
the generic template these adjustments were made in all the arcs which is a very time 
consuming task. For speeding up the radiosurgery treatment planning, after the specific 
template application, the mMLC leaves were adjusted just in those arcs with higher 
dose weights. 
4.2.5 | Treatment plan evaluation  
The treatment plan quality evaluation is accomplished through the calculation 
of dose-volume indices, the visual inspection of the dose distribution image by image 
and the analysis of the dose-volume-histograms (DVH) for the different structures, 
namely the minimum dose in the PTV, the maximum dose in the critical organs and the 
volume of the critical organs that receives more than their tolerance dose.  
The dose-volume indices assess the homogeneity of the dose distribution – 
MDPD (ratio between maximum dose and the prescribed dose) [7] – the coverage of 
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the target by the prescription isodose surface – TC (target coverage) [8] – and the 
conformity of the prescription isodose to the target volume – PITV (ratio of the 
prescription isodose surface volume to the target volume) [7] and COIN (conformity 
index) [9]. They have been reviewed in a former paper [10]. Calculated dose-volume 
indices must meet the criteria shown in Table 4.3 for a treatment plan to be acceptable. 
 
Table 4.3 – Plan quality acceptability criteria. 
Parameter Value 
TC ≥ 95% 
COIN ≥ 0.6 
PITV ≥1 & ≤ 2 
MDPD ≥1 & ≤ 2 
 
4.3 | Results and Discussion 
As previous referred the generic template is defined with six dynamic arcs with 
no specific adjustments for lesion location. The properties of this template, namely 
gantry start, stop and collimator positions are very conservative to ensure that there are 
no collisions during the treatment delivery but for specific templates properties are 
different according to the lesion location. As a large number of specific templates was 
developed, just an example is presented to outline the specificities. Table 4.4 shows the 
properties of the right generic template in black and the properties of the specific 
template named “Metastase-OCPR” in blue (OCPR = Occipital Central Posterior 
Right). 
 
Table 4.4 – Properties of the six dynamic conformal arcs for the right generic template and the specific 
template “Metastase-OCPR”. 
 
Arc Table Gantry Start Gantry Stop Collimator Weighting (%) Margin (mm) 
1 10-10 230-220 350-350 320-350 18.6-18.6 3.0-3.0 
2 37-37 220-210 340-340 320-310 16.5-16.5 3.0-3.0 
3 64-64 210-200 340-340 300-300 13.4-13.4 3.0-3.0 
4 90-90 200-200 340-340 270-270 10.3-10.3 3.0-3.0 
5 300-300 150-160 20-20 60-30 19.6-19.6 3.0-3.0 
6 335-335 140-150 10-10 45-30 21.6-21.6 3.0-3.0 
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Table positions and margin from mMLC to the PTV are the same for both 
templates and also for all specific templates. Arcs weighting in this case are also equal. 
The main difference is in gantry start positions that correspond to a larger arc amplitude 
for the OCPR template which improves the conformity of the dose distribution. 
Collimator angle changes are connected with gantry start angle changes to avoid 
collisions. 
These differences are reflected in the treatment plan quality achieved with the 
application of each plan template. Table 4.5 presents the dose-volume indices obtained 
after the application of the generic template (right or left) and the specific template OCP 
(right or left) for lesions located at Occipital Central Posterior region (right or left side). 
 
Table 4.5 – Dose-volume indices for the generic template and the template “Metastase OCP” 
application. 
 TC MDPD COIN PITV 
Generic Template 0.978±0.011 1.083±0.024 0.576±0.061 1.682±0.218 
Specific template OCP 0.979±0.010 1.081±0.024 0.581±0.059 1.671±0.211 
 
The target coverage (TC) and the minimum dose in PTV are similar for both but 
COIN and PITV indices average values reflect that the specific template provides a 
better conformity than the generic template, on average. Dose distribution homogeneity 
is also better for the specific template. TC, MDPD and PITV all comply with the plan 
acceptability criteria. The COIN value for the treatment plans obtained with the 
template OCP is on average quite close to the minimum acceptable conformity value 
of 0.6 with the direct application of the specific template.  
Due to the high number of specific templates developed (15), 13 groups were 
created to simplify the results assessment. Each group contains right, left and central 
templates, in other words, each group is identified by the first three locations, for 
example, “Metastase-OCPR” and “Metastase-OCPL” belong to the same group 
“Metastase-OCP”. 
To summarize the comparison between generic and specific templates, the 
average values of the dose-volume quality indices were calculated for the generic 
template and all specific templates and presented in Table 4.6. 
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Table 4.6 – Dose-volume indices for generic template and specific templates. 
 TC MDPD COIN PITV 
Generic Template 0.978±0.003 1.086±0.026 0.561±0.040 1.725±0.129 
Specific template 0.978±0.004 1.080±0.016 0.564±0.039 1.716±0.132 
 
In Table 4.6, PITV and COIN values indicate that specific templates provide a 
slightly better conformity than generic template. Target coverage is similar for both 
cases. The main difference is revealed by MDPD values. Homogeneity of the dose 
distribution is better for the specific template.  
After the specific template application the mMLC leaves have been adjusted for 
the heaviest arcs. 
 
Table 4.7 – Average dose-volume indices values for clinical cases of brain metastases, applying 
specific templates and with further adjustments in 1, 2, 3 and 4 arcs. 
 TC MDPD PITV COIN 
Specific template 0.978±0.004 1.080±0.016 1.716±0.132 0.564±0.039 
+ adj. in 1 Arc 0.978±0.003 1.079±0.016 1.609±0.101 0.599±0.034 
+ adj. in 2 Arcs 0.979±0.003 1.078±0.016 1.523±0.087 0.633±0.033 
+ adj. in 3 Arcs 0.978±0.004 1.073±0.012 1.436±0.069 0.670±0.029 
+ adj. in 4 Arcs 0.977±0.004 1.071±0.012 1.404±0.060 0.684±0.025 
 
Table 4.7 presents the dose-volume indices calculated for all studied clinical 
cases. Through a brief analysis we can see that on average, just the direct application 
of the specific template yields a poor conformity as for the corresponding average 
COIN. However, coverage and homogeneity already comply with the local 
acceptability criteria.  
The manual adjustment of the mMLC shape contributes for improving the 
conformity. The mMLC adjustments in 1 arc allows an increase of the conformity but 
COIN values, on average, still do not comply with the plan acceptability criteria. 
Adjustments in 2 arcs decrease PITV in 11%, on average, and improves on average in 
12% the COIN, leading to COIN values that on average comply with the plan 
acceptability criteria. With adjustments in 3 arcs COIN increases on average 19% and 
PITV decreases on average 16%. When 4 arcs are adjusted COIN values increase 21% 
and the PITV decrease 18%.  
The homogeneity of the dose distribution is improved by the mMLC 
adjustments. The target coverage is not significantly affected and can even slightly 
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decrease with it, which a consequence of the adjustment process decreasing the margin 
from the mMLC and the PTV for given incidences.  
Results presented show a strong evidence that correction of the mMLC shape in 
three arcs leads to acceptable treatment plans. Figure 4.4 presents the dose-volume 
indices for the specific template group (each point represents the average value of one 
group) plus adjustment of the mMLC in three arcs – named Optimized Plans – versus 
the same indices for the corresponding Approved Plans with corrections in all arcs. 
 
a) b)  
c) d)  
Figure 4.4 a), b), c), d) – TC, MDPD, PITV and COIN of the Optimized Plans for each metastases 
location group vs Approved Plans. 
 
Equivalent results for both plans are represented by dashed lines that have a 
slope equal to 1. For Figure 4.4 a) and d) (TC and COIN), points above the dashed line 
represent specific templates groups whose Optimized plan is better than the 
corresponding Approved Plan. For Figure 4.4 b) and c) points above the dashed line 
represent specific templates groups whose Optimized Plan could not achieve the quality 
of the corresponding Approved Plan.  
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Figure 4.4 a), b), c) and d) confirm that the correction of the mMLC shape in 
just 3 arcs produce treatment plans that are better or equivalent to the approved 
treatment plans. In 10/13 groups the target coverage (TC) of the Optimized plan is equal 
or greater than the target coverage of the Approved plan and always greater than 95% 
(the minimum acceptable value). In 12/13 groups COIN is greater than COIN of the 
Approved plans and PITV of the Optimized plans is less than the PITV of the Approved 
plans in 11/13 groups. MDPD and PITV are always less than 2.0 and COIN always 
greater than 0.6, therefore plans are on average acceptable according to these indices.  
As Table 4.7 demonstrates, the correction of just three arcs leads, on average, 
to treatment plans that comply with the treatment plan protocol.  
Applying the specific templates OCP, OSP, CIP, TIC and TCC, treatment plan 
quality with manual adjustment of the mMLC leaves for just two arcs is similar or better 
than the Approved Plans quality.  
When brain metastases are located near the brainstem or near other organ at risk, 
the dose constraint must be considered and therefore, the correction of just two or three 
arcs may not be enough. Normally the prescribed dose is greater than the organs at risk 
tolerance dose and target coverage and conformity are penalized for their sparing. 
Organs at risk prescription details were not included in any specific template group due 
to the high diversity of clinical cases.  
To summarize the comparison between Approved and Optimized Plans, the 
average values of the dose-volume quality indices were calculated and are presented in 
Table 4.8. 
 
Table 4.8 – Average values of the dose-volume quality indices for Approved treatment Plans and 
Optimized treatment Plans. 
Parameter Approved Treatment Plan Optimized Treatment Plan 
TC 0.977±0.005 0.978±0.004 
MDPD 1.079±0.020 1.073±0.012 
PITV 1.483±0.056 1.436±0.069 
COIN 0.649±0.022 0.670±0.029 
 
On average, for similar coverage, Optimized Plans are more conformal and 
homogeneous. 
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4.4 | Conclusions 
In a retrospective treatment plan analysis of patients treated from October 2012 
to August 2014 specific templates were created for each lesion location in the brain. A 
comparison between the plan quality of specific templates and that of the generic 
template standardly used at IPOCFG in the treatment planning of brain metastases was 
made. The direct application of specific templates allows on average better conformity 
and dose homogeneity. These represent a great advantage in terms of improving and 
speeding up the radiosurgery treatment planning phase.  
To improve the conformity between the target volume and the prescription 
isodose and so sparing healthy tissues and protecting the critical organs (for some brain 
metastases locations), manual adjustments still have to be made in the mMLC shape. 
The specific template application with further adjustment in just three arcs allows 
obtaining a treatment plan quality that comply the local plan acceptability criteria and 
in most cases with better conformity, homogeneity and coverage than the approved 
plans where the mMLC had been adjusted in all arcs. This optimization reduces to 
around 1/2-1/3 the treatment planning time and so, the speeding up of the radiosurgery 
treatment planning was fully accomplished.  
Furthermore, a useful graphical tool was developed to help the quick choice of 
the appropriate template to be used in each clinical case. 
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Abstract 
Purpose: To report the casuistic of all brain metastases treated with linear accelerator 
based stereotactic radiosurgery (SRS) at IPOCFG and to evaluate the outcome of SRS, 
identifying the factors that affect overall survival and local control.  
Methods and Materials: One hundred sixty eight patients with 250 brain metastases 
underwent SRS between March 2008 and December 2014. Treated lesions ranged in 
volume between 0.13 and 21.63 cm3 (mean: 3.37 ± 3.56 cm3) and the median prescribed 
dose was 20 Gy (range 12 – 24 Gy). The more frequent primary tumour sites were lung 
(43.0%), breast (24.4%) and melanoma (7.6%). Overall survival and local control were 
estimated using the Kaplan-Meier method calculated from the time of SRS. A 
multivariate Cox proportional hazards model was used to determine the prognostic 
factors for treatment outcome (overall survival and tumour local control). 
Results: The overall median survival after radiosurgery was 9 months. The 6 months, 
1 and 2 years survival rates were 62%, 39% and 22% respectively. Age and primary 
tumour location were identified as important factors affecting overall survival. The 
median time to progression of metastases was 10 months (range: 3-19 months) and local 
control was achieved in 85.2% of the evaluated brain metastases. The 6 months, 1 year 
and 2 years local control rates were 97%, 81% and 73%, respectively and no significant 
prognostic factors were associated with local progression.  
Conclusion: Stereotactic radiosurgery is an effective treatment for extending the 
survival of patients with brain metastases promoting high rates of tumour control in 
selected patients. Overall survival and local control reported results are in accordance 
with other published studies. 
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5.1 | Introduction 
Brain metastases are the most common form of brain cancer and represent a 
significant cause of morbidity and mortality among cancer patients. According to the 
American Society for Radiation Oncology, brain metastases develop in 20-40% of 
cancer patients that have, predominantly, a primary tumour located in lung, breast, skin, 
kidney or colon-rectum [1].  
Clinical manifestations can include focal neurological deficits depending on the 
lesion location, seizures, raised intracranial pressure, impairment in cognition and in 
functional status. Nowadays, with the growing use of magnetic resonance imaging 
more cases are being detected while still asymptomatic [2].  
Historically, the life expectancy of patients with brain metastases is poor, but 
the outcome is more favourable in younger patients (less than 65 years old), with a 
single, small and asynchronous brain metastases, a controlled primary tumour, a 
Karnofsky performance status (KPS) ≥ 70 and without systemic metastases [2]. 
Current treatment options include neurosurgical resection, whole-brain 
radiation therapy (WBRT), stereotactic radiosurgery, chemotherapy or some 
combination of these. The choice of one modality over the others depends on the 
presence of multiple factors related to patients (age, performance status), tumour 
characteristics (number and size of the metastases, tumour type, extracranial disease 
activity), clinical situation and available treatment options [2,3].   
Conventional WBRT is still frequently applied as a standard therapy for 
treatment of patients with brain metastases, namely for multiple brain metastases and 
patients with disseminated disease with poor prognosis. Side effects due to toxicity to 
the normal volume of the brain and lack of sustained local efficacy make this irradiation 
technique not the first option in patients with good systemic prognosis. Stereotactic 
radiosurgery (Gamma Knife or linear accelerator-based) has become a current 
treatment for those patients that have lesions smaller than 3-4 cm in diameter. It has 
been demonstrated in several randomized trials that stereotactic radiosurgery (SRS) 
accomplishes highly effective and predictable local control for single and multiple brain 
metastases, even for conventionally radioresistant metastases from melanoma or renal 
cancer [4-6]. Moreover, on neuroimaging, brain metastatic lesions usually appear fairly 
spherical and well-defined, therefore they are a suitable target for SRS treatment. 
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Remote brain metastases are reported in 33-42% after WBRT [7,8] and in 39-
52% after radiosurgery [9-11]. Radiosurgery can be used repeatedly for remote 
recurrences or new metastases after WBRT, while WBRT is generally applied only 
once. 
Brain metastases smaller than 3-4 cm in diameter represent an ideal target for 
SRS due to the spherical shape, distinct radiographic and pathologic margins and their 
tendency to displace rather than invade adjacent brain tissue. SRS allows the treatment 
of brain metastases in almost any location, including eloquent or deep regions that could 
be difficult or impossible to access surgically. The main disadvantages of radiosurgery 
are its inability to quickly address the symptoms caused by the mass effect, limited 
application for lesions larger than 3-4 cm in diameter and metastatic lesions located in 
or near structures with low tolerance to radiation such as optic nerves, chiasm or 
brainstem and possible functional changes [12]. SRS is not recommended in brain 
metastases larger than 3-4 cm in diameter due to the increased risk of a later edema 
development and normal brain tissue damage. In these cases, surgical resection should 
be considered in patients with controlled systemic disease and with metastases in an 
accessible location [2]. Hypofractionated radiosurgery delivered in 3-5 fractions over 
multiple days is another alternative therapeutic option [13]. Patients with brain 
metastases that cause compression of neuronal functional structures or intracranial 
hypertension may undergo surgery in order to achieve better outcome [2]. 
The purpose of this work was to report the casuistic of all brain metastases 
treated at IPOCFG with linear accelerator (LINAC)-based radiosurgery from March 
2008 to December 2014 and evaluate the treatment outcome, identifying the factors that 
may influence overall survival and local control. 
 
5.2 | Methods and Materials  
5.2.1 | Lesion characteristics and SRS procedures  
One hundred and sixty eight patients (87 females and 81 males) with 250 
metastases underwent SRS between March 2008 and December 2014. In 108 patients 
only one metastase was treated (64.3%), in 43 patients two metastases were treated 
(25.6%), three lesions were treated in 13 patients (7.7%) and four or more lesions were 
treated in 4 patients (2.4%).   
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 Lesions characteristics are listed in Table 5.1. The patients average age at the 
time of SRS was 60 years old (range 22-89 y) and the most common primary tumour 
sites were lung (43.0%), breast (24.4%) and melanoma (7.6%). The other group of 
primary tumours includes ovary, prostate, kidney, thyroid and colon-rectum locations, 
for example. The most common locations in the brain were parietal lobe (36%) 
followed by temporal (19.2%) and occipital lobe (19.2%).  
The mean planning target volume (PTV) was 3.37 ± 3.56 cm3 (range 0.13 – 
21.63 cm3) and the median prescribed dose was 20 Gy (range 12 – 24 Gy). The average 
values of the dose-volume indices were: 0.98 ± 0.03 for the coverage index, 1.08 ± 0.04 
for the homogeneity index and 0.64 ± 0.07 for the conformity index. 
 
Table 5.1 – Summary of lesion characteristics and dose-volume indices. 
Parameter Value 
Number of patients 168 
Number of treated lesions 250 
Mean age (range) 60 (22-89) 
Sex(F/M) 87/81 
Number of  treated lesions per patient 
1 lesion 
2 lesions 
3 lesions 
4 lesions 
more than 4 lesions 
 
108 (64.3%) 
43 (25.6%) 
13 (7.7%) 
3 (1.8%) 
1 (0.6%) 
Primary tumour location 
Lung 
Breast 
Skin 
Others 
 
74 (43.0%) 
42 (24.4%) 
13 (7.6%) 
43 (26%) 
Lesions location 
frontal 
parietal 
temporal 
occipital 
cerebellar 
 
                24 (9.6%) 
90 (36.0%) 
48 (19.2%) 
48 (19.2%) 
40 (16.0%) 
Treated volume (cm3) 
Mean (range) 
 
3.37 (0.13-21.63) 
Mean prescribed dose (Gy) 19.33 ± 2.23 
Mean TC1 (%) 0.98 ± 0.03 
Mean MDPD2 1.08 ± 0.04 
Mean COIN3 0.64 ± 0.07 
1 TC= Target Coverage [14] 
2MDPD= Maximum Dose to Prescribed Dose [15] 
3COIN= Conformity Index [16] 
 
Each patient was immobilised with the Brainlab Stereotactic Headring and 
underwent 1.5 mm slice thickness computed tomography (CT) scans (with and without 
contrast) on a dedicated big-bore CT simulator (Siemens Sensation Open) with the 
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Brainlab CT Localizer. High-resolution 3D T1 weighted single dose gadolinium 
contrast (0.1 mmol/kg) 1.5T magnetic resonance (MR) images of the whole brain were 
also obtained for all patients, usually within a week of planned treatment. Both CT and 
MR images were electronically transferred to the therapy planning system (iPlan RT 
Dose v4.5, BrainLAB) for co-registration. All fusions were visually inspected and 
approved by the neuroradiologist. The PTV corresponded to the delineated target 
volume plus a 1 mm isotropic margin. 
Treatment plans were computed using a pencil beam algorithm for a 6 MV 
photon beam energy. A dose resolution of 1 mm was set. The adaptive grid option was 
used for the calculation of the dose matrix. In this option the dose grid size is 
automatically adapted to the volume of small structures and so guarantees at least 10 
voxels are always used for dose computation in all directions. SRS was performed using 
the micro-multileaf collimatior (mMLC) of Brainlab, with full advanced integration in 
a Siemens Oncor Avant-Garde linear accelerator using the 6MV photon mode. 
Clinical records of these patients including basic information (ID, gender, year 
of birth, primary tumour and date of death (when it occurred)), treatment and quality 
control (date, treatment duration, dosimetric parameters) and follow-up details (number 
of imagiologic controls, number and date of follow-up clinical appointments) were 
stored in a dedicated database. This database was developed in-house using MySQL 
Workbench Visual Database Designer version 3.2 CE. 
5.2.2 | Follow-up and outcomes analysis  
The median clinical follow-up after radiosurgery was 7 months for the 
considered range of 1-24 months. Despite the maximum follow-up time of our series 
being 69 months, eighteen patients with longer follow-up time have been censured at 
24 months to prevent degradation of the statistical power of the study. Patients were 
examined clinically one month after radiosurgical treatment and then every 2/3 months 
or as appropriate according to the neurologic conditions. Imagiologic control (MR/CT) 
was done every 3/4 months or also as appropriate according to the neurologic 
conditions. 
Lesion’s diameters were measured in two dimensions and in every image 
control set in order to assess the outcome of the treatment. Response to radiosurgery 
was not evaluated in 88 metastatic lesions due to patient’s death before the date for the 
first imagiologic control, insufficient data or very recent treatment. Therefore, 162 
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metastases were eligible for local control analysis. Tumour response was classified 
according to Macdonald 2D criteria [17]. MacDonald’s criteria proposed four 
categories to treatment outcome: complete response (CR), a complete disappearance of 
tumour; partial response (PR), at least 50% decrease in tumour size; progressive disease 
(PD), at least 25% increase in tumour size and stable disease (SD) neither PR nor PD. 
5.2.3 | Statistical analysis 
Overall survival and tumour local control of the patients that underwent SRS 
were estimated using the Kaplan-Meier method calculated from the time of SRS.  The 
following factors were tested in order to assess their influence in overall survival: age 
(< 65y and ≥ 65y), number of treated brain metastases (1 vs >1) and primary tumour 
sites (breast vs lung vs other). Metastases location, metastases volume, primary tumour 
location and patient’s age were tested in order to assess their influence in local control.  
Comparisons between groups were performed using the log-rank test. A 
multivariate Cox proportional hazards model was used to determine the prognostic 
factors for treatment outcome (overall survival and local control). Factors found 
significant in the crude model were included in the final model. A probability value ≤ 
0.05 was considered statistically significant.  
Statistical analysis was performed using R version 3.1.2 software. 
 
5.3 | Results 
5.3.1 | Overall Survival 
Median overall survival for the entire group was 9 months (95% Confidence 
Interval (CI) 8-12 months) from the date of their first radiosurgery. The 6 months, 1 
year and 2 years survival rates were 62%, 39% and 22%, respectively – Figure 5.1.  
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Figure 5.1 – Kaplan-Meier analysis of overall survival. 
 
Univariate analysis showed that age and primary tumour location were 
significant predictive factors for survival (p<0.05) – Table 5.2. 
 
Table 5.2 – Univariate survival and multivariate survival analysis. 
Variable No of patients 
Survival time Median 
(months) 
Univariate 
Analysis 
Multivariate 
Analysis 
Hazard Ratio 
(95 % CI) 
Hazard Ratio 
(95 % CI) 
Age (years) 
< 65 
≥ 65 
 
104 
64 
 
12 
7 
 
0.63 (0.42-0.93) 
1 
 
_ 
No of brain 
metastases 
1 
>1 
 
109 
59 
 
9 
12 
 
0.88 (0.60-1.29) 
1 
 
_ 
 
Primary Tumour 
Breast cancer 
Lung cancer 
Others 
 
42 
74 
52 
 
13 
9 
6 
 
1 
1.40 (0.86-2.28) 
1.80 (1.07-3.01) 
 
1 
1.30 (0.79-2.13) 
1.77 (1.06-2.97) 
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Cox proportional hazards regression indicates that the risk of patients with less 
than 65 years old to die earlier after SRS is lower than the risk associated to patients 
with an age greater than 65 years old (hazard ratio = 0.63, 95% confidence interval = 
0.42 to 0.93, p=0.020). 
Median survival time for patients with breast cancer that underwent SRS was 
13 months, for patients with lung cancer was 9 months and for patients with other 
cancer was 6 months. Cox model points to a statistic significant difference in overall 
survival between Breast cancer and Other cancer groups (hazard risk = 1.80, 95% 
confidence interval = 1.07 to 3.01, p=0.026). Figure 5.2 shows a comparison of overall 
survival for the different primary tumour groups (breast cancer, lung cancer and other). 
 
 
Figure 5.2 – Comparison of different primary tumour locations with respect to survival. 
 
Age and primary tumour location were included in a multivariate analysis of 
outcome performed using a Cox proportional hazards regression model.  
In the multivariate analysis primary tumour and age proved to be significant 
variables (p<0.05). Cox model demonstrates that regardless of age, there remains a 
statistic significant difference in overall survival between Breast cancer and Other 
cancer groups (hazard ratio = 1.77, 95% confidence interval = 1.06 to 2.97, p=0.030). 
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5.3.2 | Local Control 
One hundred sixty two metastases were eligible for local control analysis. Local 
control was achieved in 85.2% of the evaluated brain metastases and the median time 
to lesion progression was 10 months (range: 3-19 months). Applying Macdonald’s 
criteria to our metastases series, a complete response (CR) was noted in 18 metastases 
(11.1%), partial response (PR) in 11 metastases (6.8%), a stable disease (SD) in 109 
metastases (67.3%) and a progressive disease (PD) in 24 brain metastases (14.8%).  
Figure 5.3 shows the local control curve.  
 
Figure 5.3 – Kaplan-Meier analysis of local control. 
 
The 6, 12 and 24 months actuarial rates without local failure after SRS were 
97%, 81% and 73%, respectively.  
In univariate analysis, metastases location, metastases volume, primary tumour 
location and patient’s age were not significantly correlated with local control rate. 
 
5.4 | Discussion 
In the present study we have evaluated the clinical outcome in 168 consecutive 
patients treated with SRS from March 2008 till December 2014, with 250 brain 
metastases. Median overall survival for the entire group was 9 months (95% 
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Confidence Interval 8-12 months) from the date of their first radiosurgery. The 6 
months, 1 year and 2 year survival rates were 62%, 39% and 22%. These results are in 
accordance with previous studies that report median survival ranging from 6-14 months 
for brain metastases [8, 18-21]. 
Univariate analysis showed that age and primary tumour location were 
significant predictive factors for survival (p<0.05) – Table 5.2. The number of brain 
metastases had not a significant impact on survival, similarly to some recent studies 
[21-23] and differently from earlier published series [24].  
In univariate analysis, Cox proportional hazards regression indicates that the 
risk of patients with less than 65 years old to die earlier after SRS is lower than the risk 
associated to patients with an age greater than 65 years old (hazard ratio = 0.63, 95% 
confidence interval = 0.42 to 0.93, p=0.020). Furthermore, Cox model points to a 
statistic significant difference in overall survival between Breast cancer and Other 
cancer groups (hazard risk = 1.80, 95% confidence interval = 1.07 to 3.01, p=0.026) 
which means that from our data we just may conclude that breast cancer metastases 
have  a larger survival rate than any other cancer type.   
In multivariate analysis primary tumour and age proved to be significant 
variables (p<0.05). In this case, Cox model allows to say that regardless of age, the risk 
of earlier death for patients with a primary tumour located in the lung is, on average,  
30% (hazard ratio = 1.30, 95% confidence interval = 0.79 to 2.13, p=0.303) greater than 
the same risk associated to patients with a primary tumour in the breast; the risk that a 
patient dies earlier when the primary tumour belongs to the Other cancer group is on 
average 77% (hazard ratio = 1.77, 95% confidence interval = 1.06 to 2.97, p=0.030) 
greater than the risk associated to patients with a primary tumour in the breast. Finally, 
the risk associated to patients whose primary tumour belongs to the Other cancer group 
is on average 29% (hazard ratio=1.29, 95% confidence interval = 0.85 to 1.95, p=0.231) 
greater than in patients whose primary tumour is located in the lung. However just the 
difference between Breast and Other groups is statistically significant. 
These results are in accordance with previous series of SRS for brain metastases 
that report a slightly higher prognostic for patients with a primary tumour located in the 
breast when compared to other groups of cancer patients [23,25-28].  
Similarly to other reports on SRS, we used a definition of local progression 
proposed by Macdonald’s, based on imagiologic control [20,29]. Local control was 
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achieved in 85.2% of the evaluated brain metastases and the median time to lesion 
progression was 10 months (range: 3-19 months). The 6, 12 and 24 months actuarial 
rates without local failure after SRS were 97%, 81% and 73%, respectively. 
Comparable outcomes were achieved in other SRS retrospective series. Molenaar et al. 
in an analysis of 86 patients with brain metastases that underwent SRS reported local 
control rates of the 82%, 63% and 57% at 6, 12 and 24 months respectively [20]. 
Similarly, Bernard et al. reported actuarial local control at 6 months and 12 months of 
87% and 68% on a study of 54 patients with a total of 103 metastases treated with SRS 
[30].  
No significant prognostic factors were associated with local control. Several 
groups have reported that higher prescription doses (prescribed dose greater than 18 
Gy) and small tumour volume are associated with better tumour control [20, 31-34]. 
Some radiosurgery series also described primary tumour site correlation with local 
control. Reported rates were 90–94% for breast cancer metastases [35-38] and 81–98% 
for brain metastases of lung cancer [39, 40], 73–90% for melanoma [41,42] and 83–
96% for renal cell cancer [40,43,44]. Garsa et al. [33] retrospectively analysed 228 
patients with 401 brain metastases from non-small cell lung cancer and they found 
higher risk of local failure for cerebellar metastases. The same conclusions were 
reported by Sansur et al. [45] and Alexander et al. [34]. 
Although local control of the treated metastases could be essential for the 
neurologic integrity and quality of life, it may not have direct impact on patient’s 
survival due to the influence of the characteristics and status of the systemic disease in 
patient’s outcome [46-48]. 
 
5.5 | Conclusion 
Overall survival, local control and factors that may influence treatment outcome 
were evaluated in 168 patients treated with SRS in 250 metastases between March 2008 
and December 2014 at IPOCFG. Median overall survival was 9 months from the date 
of the SRS for a follow up time of 24 months. The 6 months, 1 year and 2 years survival 
rates were 62%, 39% and 22%, respectively. These results are in accordance with other 
published studies that report a median survival ranging from 6-14 months. Statistical 
analysis showed that age and primary tumour location were significant predictive 
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factors for survival, whereas the number of brain metastases was not shown to be a 
significant factor. 
Local control was achieved in 85.2% of the evaluated brain metastases. The 6, 
12 and 24 months actuarial rates without local progression after SRS were 97%, 81% 
and 73%, respectively. No significant factors were associated with the local tumour 
progression.  
The reported outcome of SRS was comparable to previous studies. These results 
support the conclusions that SRS provides a high local control rate, improves the 
cumulative survival and may be associated to low normal tissue complication 
probability. Based on identified prognostic factors, the selection of eligible patients is 
an important concern to maximize radiosurgery benefits. 
  
SRS of brain metastases: analysis of outcome | 79 
 
 
5.6 | References  
[1] Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, et al. 
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-
based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol 
Phys 2005; 63:37-46 
[2] Soffietti R, Cornu P, Delattre JY, Grant R, Graus F, Grisold W, et al. Brain 
metastases. In: Gilhus NE, Barnes MP, Brainin M, ed: European Handbook of Clinical 
Neurological Management. Vol. 1, 2nd Edition, Blackwell Publishing Ltd, 2011, 
pp.437-445 
[3] Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, et al. 
Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): 
An American Society for Radiation Oncology evidence-based guideline. Practical 
Radiation Oncology 2012; 2:210-25 
[4] Noel G, Valery AC, Boisserie G, Cornu P, Hasboun D, Marc SJ et al. LINAC 
radiosurgery for brain metastases of renal cell carcinoma. Urologic Oncology 2004; 
22:25-31 
[5] Manon R, O’ Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, et al. 
Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from 
renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology 
Group study (E 6397). J Clin Oncol 2005; 23:8870-6 
[6] Gaudy-Marqueste C, Regis JM, Muracciole X, Laurans R, Richard MA, 
Bonerandi JJ, et al. Gamma-Knife radiosurgery in the management of melanoma 
patients with brain metastases: a series of 106 patients without whole-brain 
radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65(3):809-16 
[7] Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. 
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical 
resection of one to three cerebral metastases: results of the EORTC 22,952–26,001 
study. J Clin Oncol 2011; 29(2):134-41 
[8] Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. 
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic 
radiosurgery alone for treatment of brain metastases: a randomized controlled trial. 
JAMA 2006; 295(21):2483-91 
[9] Chidel MA, Suh JH, Reddy CA, Chao ST, Lundbeck MF, Barnett GH. 
Application of recursive partitioning analysis and evaluation of the use of whole brain 
radiation among patients treated with stereotactic radiosurgery for newly diagnosed 
brain metastases. Int J Radiat Oncol Biol Phys 2000; 47(4):993-99 
[10]  Shirato H, Takamura A, Tomita M, Suzuki K, Nishioka T, Isu T, et al. Stereotactic 
irradiation without whole-brain irradiation for single brain metastases. Int J Radiat 
Oncol Biol Phys 1997; 37(2):385-91 
[11]  Chougule PB, Burton-Williams M, Saris S, Zheng Z, Ponte B, Noren G, et al. 
Randomized treatment of brain metastases with gamma knife radiosurgery, whole brain 
radiotherapy or both. Int J Radiat Oncol Biol Phys 2000; 48(3):114 
[12]  Hsu H, Rush S, Min C, Golfinos JG. Local Control of Low-Volume Brain 
Metastasis Using Sterotactic Radiosurgery. In: Hayat MA, ed: Tumours of the Central 
Nervous System. Vol. 11, Springer Science+Business Media Dordrecht, 2014, 141-155 
[13]  Eaton B, Gebhardt B, Prabhu R, Hui-Kuo Shu, Walter J Curran, Ian Crocker. 
Hypofractionated radiosurgery for intact or resected brain metastases: defining the 
optimal dose and fractionation. Radiation Oncology 2013; 8:135 
80 | References 
 
 
 
[14]  Lomax NJ, Scheib SG. Quantifying the degree of conformity in radiosurgery 
treatment planning Int. J. Radiat Oncolo Biol Phys 2003; 55:1409-19 
[15]  Shaw E, Kline R, Gillin M, Souhami L, Hirschfeld A, Dinapoli R, et al. Radiation 
Therapy Oncology Group: Radiosurgery quality assurance guidelines. Int J Radiat 
Oncol Biol Phys 1993; 27:1231-9 
[16]  Baltas D, Kolotas C, Geramani K, Mould RF, Ioannidis G, Kekchidi M, et al. A 
conformal index (COIN) to evaluate implant quality and dose dose specification in 
brachytherapy. Int J Radiat Oncol Biol Phys 1998; 40(2): 515-24 
[17]  Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for 
phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8(7):1277-80 
[18]  Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. 
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical 
resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. 
J Clin Oncol 2011; 29:134-41 
[19]  Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G,  Bozzao A, et al. 
Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain 
radionecrosis. Radiation Oncology 2011; 6:48 
[20]  Molenaar R, Wiggenraad R, Verbeek KA, Walchenbach R, Vecht C. 
Relationship between volume, dose and local control in stereotactic radiosurgery of 
brain metastases. J Neurosurg 2009; 23(2):170-8 
[21]  Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et 
al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for 
patients with one to three brain metastases: phase III results of the RTOG 9508 
randomised trial. Lancet 2014; 363:1665-72 
[22]  Manon R, O'Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, et al. 
Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from 
renal cell carcinoma, melanoma, and sarcoma: Eastern Cooperative Oncology Group 
study (E 6397). J Clin Oncol 2005; 23:8870-76 
[23]  Muacevic A, Kreth FW, Tonn JC, Wowra B. Stereotactic radiosurgery for 
multiple brain metastases from breast carcinoma. Cancer 2004; 100:1705-11 
[24]  Joseph J, Adler JR, Cox RS, Hancock SL. Linear accelerator-based stereotaxic 
radiosurgery for brain metastases: the influence of number of lesions on survival. J Clin 
Oncol1996; 14:1085-92 
[25]  Firlik KS, Kondziolka D, Flickinger JC, Lunsford LD. Stereotactic radiosurgery 
for brain metastases from breast cancer. Ann Surg Oncol 2000; 7(5):333-8 
[26]  Kased N, Binder DK, McDermott MW, Nakamura JL, Huang K, Berger MS, et 
al. Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int J 
Radiat Oncol Biol Phys 2009; 75(4):1132-40 
[27]  Goyal S, Prasad D, Harrell F Jr, Matsumoto J, Rich T, Steiner L. Gamma knife 
surgery for the treatment of intracranial metastases from breast cancer. J Neurosurg 
2005; 103(2):218-23 
[28]  Levin KJ, Youssef EF, Sloan AE, Patel R, Zabad RK, Zamorano L. Gamma knife 
radiosurgery in patients with advanced breast cancer undergoing bone marrow 
transplant. J Neurosurg 2002; 97(5):663-5 
[29]  Takumura A, Shirato H, Saito H, Sakurai  Y. Factors Associated with Tumor 
Response and Survival in Radiosurgery for Brain Metastasis. Int J Clin Oncol 1996; 
1:23-30 
SRS of brain metastases: analysis of outcome | 81 
 
 
[30]  Bernard ME, Wegner RE, Reineman K, Heron DE, Kirkwood J, Burton SA, et al. 
Linear accelerator based stereotactic radiosurgery for melanoma brain metastases. J 
Cancer Res Ther 2012; 8(2):215-21 
[31]  Vogelbaum MA, Angelov L, Lee SY, Li L, Barnett GH, Suh JH. Local control of 
brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J 
Neurosurg 2006; 104:907-912 
[32]  Shiau CY, Sneed PK, Shu HK, Lamborn KR, McDermott MW, Chang S, et al. 
Radiosurgery for brain metastases: Relationship of dose and pattern of enhancement to 
local control. Int J Radiat Oncol Biol Phys 1997; 37:375-83 
[33]  Garsa AA, Badiyan SN, DeWees T, Simpson JR, Huang J, Drzymala RE, et al. 
Predictors of Individual Tumor Local Control After Stereotactic Radiosurgery for Non-
Small Cell Lung Cancer Brain Metastases. Int J Radiat Oncol Biol Phys 2014; 
90(2):407-13 
[34]  Alexander E, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, et al. 
Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. 
J Natl Cancer Inst 1995; 87:34-40 
[35]  Amendola BE, Wolf AL, Coy SR, Amendola M, Bloch L. Gamma knife 
radiosurgery in the treatment of patients with single and multiple brain metastases from 
carcinoma of the breast. Cancer J 2000; 6(2):88-92 
[36]  Firlik KS, Kondziolka D, Flickinger JC, Lundsford LD. Stereotactic radiosurgery 
for brain metastases from breast cancer. Ann Surg Oncol 2000; 7(5):333-8 
[37]  Kondziolka D, Kano H, Harrison GL, Yang HC, Liew DN, Niranjan A, et al. 
Stereotactic radiosurgery as primary and salvage treatment for brain metastases from 
breast cancer. J Neurosurg 2011; 114(3):792-800 
[38]  Muacevic A, Kreth FW, Tonn JC, Wowra B. Stereotactic radiosurgery for 
multiple brain metastases from breast carcinoma. Cancer 2004; 100(8):1705-11 
[39]  Hoffman R, Sneed PK, McDermott MW, Chang S, Lamborn KR, Park E, et al. 
Radiosurgery for brain metastases from primary lung carcinoma. Cancer J 2001; 
7(2):121-31 
[40]  Serizawa T, Ono J, Iichi T, Matsuda S, Sato M, Odaki M, et al. Gamma knife 
radiosurgery for metastatic brain tumors from lung cancer: a comparison between small 
cell and non-small cell carcinoma. J Neurosurg 2002; 97(5):484-8 
[41]  Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD. 
Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local 
disease control and survival. Int J Radiat Oncol Biol Phys 1998; 42(3): 581-9 
[42]  Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, et al. 
Outcome predictors of Gamma Knife surgery for melanoma brain metastases. J 
Neurosurg 2011; 114(3):769-79 
[43]  Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery in 
patients with renal cell carcinoma metastases to the brain: long-term outcomes and 
prognostic factors influencing survival and local tumor control. J Neurosurg 2003; 
98(2):342-49 
[44]  Shuto T, Inomori S, Fujino H, Nagano H. Gamma knife surgery for metastatic 
brain tumors from renal cell carcinoma. J Neurosurg 2006; 105(4):555-60 
[45]  Sansur CA, Chin LS, Ames JW, Banegura AT, Aggarwal S, Ballesteros M, et al. 
Gamma knife radiosurgery for the treatment of brain metastases. Stereotact Funct 
Neurosurg 2000; 74(1):37-51 
82 | References 
 
 
 
[46]  Sperduto PW, Kased N, Roberge D, Chao ST, Luo X, Sneed PK et al. The effect 
of tumor subtype on the time from primary diagnosis to development of brain 
metastases and survival in patients with breast cancer. J Neurooncol 2013; 112(3):467-
72 
[47]  Xu Z, Schlesinger D, Toulmin S, Rich T, Sheehan J. Impact of triple-negative 
phenotype on prognosis of patients with breast cancer brain metastases. Int J Radiat 
Oncol Biol Phys 2012; 84(3):612-18 
[48]  Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet 
Oncol 2013; 14(6):218-28 
  
 
CHAPTER 6 
Dosimetric comparison of multileaf 
collimator systems for intracranial stereotactic 
radiosurgery 
 
Tânia Santos1, Tiago Ventura2, Miguel Capela2, Maria do Carmo Lopes2 
1 Physics Department, University of Coimbra, Coimbra, Portugal  
2 Medical Physics Department, IPOCFG, E.P.E., Coimbra, Portugal  
 
 
6 | Dosimetric Comparison of multileaf collimators systems for 
intracranial stereotactic radiosurgery 
 
 
 
  
 
  
Dosimetric comparison of multileaf collimator systems for intracranial SRS | 85 
 
 
Abstract 
Purpose: At IPOCFG, stereotactic radiosurgery is performed using a micro-multileaf 
collimator (3mm minimum leaf width), mMLC m3, with full advanced integration in a 
linear accelerator. This work aimed to evaluate if the replacement of the standard 82-
leaf multileaf collimator with 1cm leaf width, by a 160MLC (MLC-160) with 5mm leaf 
width, would allow to dispense the use of the m3 without compromising the treatment 
plans quality. 
Methods and Materials: 67 metastases and 23 meningiomas formed the basis of this 
retrospective planning study. For each clinical case two treatment plans were generated: 
one using the m3 and the other using the MLC-160. The same irradiation technique, 
with multiple noncoplanar conformal arcs, was used and all arc parameters were kept 
the same. The dosimetric differences from both plans were quantified in terms of target 
coverage and dose conformity. Dose-volume histograms for the planning target volume 
(PTV) and the organs at risk (OARs) were also recorded and analysed. The Wilcoxon 
signed rank test was performed to evaluate statistical differences.  
Results: The characteristics associated with the MLC-160 system (larger leaf width 
and static conformal arcs) contributed to a poorer dose conformity, mainly for irregular 
shaped or small lesions and for lesions at close proximity to OARs. Statistically 
significant differences were found in terms of the minimum dose for lesions ≤ 0.5 cm3 
and irregular lesions.  As a consequence, almost 35% of the considered clinical plans 
would not be clinically acceptable if the intended replacement of the collimation system 
would take place.  
Conclusion: The mMLC yields dosimetric benefits in radiosurgery. The treatment of 
lesions with complex shapes or at close proximity to OARs do benefit from the use of 
a fine leaf-width MLC.  
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6.1 | Introduction 
Stereotactic Radiosurgery (SRS) is a treatment technique characterized by the 
administration of high doses of radiation in a single fraction with high accuracy to a 
small and well-defined intracranial target, while limiting the dose to surrounding 
normal tissues [1].  
In the early development of linear accelerator (LINAC)-based systems, circular 
collimators of different diameters coupled to the LINAC were used and the SRS 
treatment was performed with multiple convergent and noncoplanar arcs [2,3]. Since 
then, LINAC-based SRS has become highly sophisticated. The introduction of the 
multileaf collimator (MLC) has incorporated new features to radiotherapy and also the 
SRS process, enabling the generation of irregular field shapes allowing improvements 
in conformity and homogeneity of the dose distribution [1].  
The impact of the narrower leaf widths on radiotherapy treatment planning has 
been studied by many authors, but with mixed results [1-10]. Kubo et al. [7] were the 
first to analyse the impact of the MLC leaf width on stereotactic radiosurgery and 3D 
conformal radiotherapy treatment plans, using 1.7, 3 and 10 mm leaf width MLC 
systems. They showed that for radiosurgery treated lesions, the 1.7 and 3 mm leaf width 
allowed to comply the RTOG (Radiation Therapy Oncology Group) treatment planning 
guidelines for SRS, in most cases. On the other hand, Burmeister et al. [9], reported no 
apparent clinically advantage in the replacement of a 10 mm by a 5 mm MLC system 
on patients treated with intensity-modulated radiotherapy, except for very small target 
volumes or those with concavities that are small with respect to the MLC leaf width. 
More recently, Tanyi et al. [10] performed a dosimetric comparison between MLC 
systems with 2.5 mm and 5 mm leaf width for the SRS treatment of 68 intracranial 
lesions and demonstrated small dosimetric benefits of the 2.5mm leaf width MLC 
system over the 5mm leaf width system.   
The present study aimed at justifying a management decision on the 
replacement of the standard 82-leaf Optifocus MLC collimator (1 cm leaf width at 
isocenter) installed in the Siemens Oncor Avant Garde linear accelerator presently used 
for SRS with a tertiary BrainLab mMLC (m3). We would like to evaluate if the 
replacement of the 82-leaf MLC by a 160 MLC with 5 mm leaf width at isocenter would 
enable to dispense the use of the m3 mMLC without significantly jeopardizing the 
quality of the treatment plans. This evaluation would include quantifying the amount 
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of the eventual losses in terms of plan quality and assessing the characteristics of the 
lesions that would mostly be affected by the eventual replacement. 
 
6.2 | Methods and Materials 
At IPOCFG SRS is performed since February 2008 using the micro-multileaf 
collimator mMLC of BrainLab (3 mm minimum leaf width) – m3, with full advanced 
integration in a Siemens Oncor Avant-Garde linear accelerator using the 6 MV photon 
mode. The treatment technique consists in 6-7 dynamic conformal arcs rotating about 
a single isocenter using the m3 to conform to the target volume every 10º incidence. 
6.2.1 | Patients selection 
For the proposed retrospective planning study, 67 metastatic brain lesions and 
23 meningiomas treated with SRS between November 2008 and December 2014 have 
been selected. The clinical cases were categorised into four groups: (I) brain metastases 
with volume ≤ 0.5 cm3 (n=36), (II) brain metastases with volume > 0.5 cm3 (n=16), (III) 
brain metastases located in close proximity to organs at risk (n=15) and (IV) 
meningiomas (n=23). Table 6.1 summarizes the group’s characteristics.  
 
Table 6.1 – Summary of group’s characteristics. 
Parameter 
group I 
(Metastases) 
group II 
(Metastases) 
group III 
(Metastases) 
group IV 
(Meningioma) 
No. of lesions 36 16 15 23 
Average Target 
Volume (±1) (cm3) 
0.30 ± 0.12 3.40 ± 2.82 3.80 ± 3.18 3.90 ± 3.03 
Organ(s) at risk None None Brainstem 
 Brainstem, 
optical nerves, 
chiasm 
 
The groups were created to represent the different clinical situations in our SRS 
experience. Groups I and II were intended to compare the volume effect, group III for 
critical organ sparing and group IV was chosen for shape effect assessment. As 
meningioma cases may appear in any brain location, including at close proximity to 
critical structures, some cases in group IV were also compared for critical organ 
sparing.  
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6.2.2 | Collimators 
The m3 has 26 pairs of leaves: from centre to periphery 14 pairs with 3 mm 
width, six pairs with 4.5 mm and six pairs with 5.5 mm width. The maximum possible 
field size is 10 × 10 cm2 at isocenter. It is a tertiary or additional collimator which must 
be attached to the LINAC head every time a stereotactic treatment is to be delivered. 
The irradiation technique is based on dynamic conformal arcs using in almost all cases 
a single isocenter for each lesion. During irradiation, the gantry is rotating while the 
leaves of the mMLC move according to the beam’s eye view (each leaf of the m3 moves 
linearly at 10° intervals interpolating from the initial position to the next calculated 
position) – Figure 6.1. 
 
 
Figure 6.1 – Beam’s eye view of single 130° dynamic arc for 3-mm micro-MLC (m3) showing the 
collimator leaves position for each 10° interval between 220°-290°. 
 
The Siemens 160 Multileaf Collimator has 160 leaves – 80 on each bank with a 
leaf width of 5 mm at isocenter over the full maximum field size of 40×40 cm2. It is 
integrated on the LINAC head replacing the X-jaws. The irradiation technique is based 
on static conformal arcs as the Oncor Avant-Garde linac does not include the dynamic 
irradiation mode. The radiation field is adjusted to the largest shape of the target lesion 
in just one incidence per arc. During irradiation, the gantry is rotating and the MLC 
shape remains static– Figure 6.2. 
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Figure 6.2 – Beam’s eye view of single 130° static arc for 5-mm multileaf collimator (MLC-160) 
showing collimator leaves position for each 10° interval between 220°-290°. 
 
6.2.3 | Machine Profiles Comparison  
The current study is not just a simple comparison of different MLC leaf widths. 
It also includes the assessment of two dose delivery systems associated to each MLC. 
The micro-multileaf collimator of BrainLab is the collimator system used at our 
institution for SRS treatments. The corresponding basic dosimetry was locally 
performed during the commissioning process and the dosimetric database was stored 
in the Physics Administration module (PAM) of the treatment planning system (iPlan, 
BrainLab). For the present study, BrainLab provided a full dosimetric database of an 
external linear accelerator of the same model (Oncor) equipped with a Siemens 160 
Multileaf Collimator which was stored as a new Machine Profile in PAM.  
Before starting the retrospective planning study, a dosimetric comparison 
between the basic dosimetry databases corresponding to the two delivery systems was 
performed to evaluate if the characteristics of the radiation field were comparable and 
to validate the external machine dosimetry. For the m3 the local nominal linac output 
for a 10×10 cm2 field size with source surface distance of 100 cm and at a depth of 5 
cm was 0.867 Gy/100 MU (monitor units). For the external MLC-160 system the 
nominal linac output was defined for a 10×10 cm2 with source surface distance of 100 
cm and at a depth of 10 cm as 0.677 Gy/100 MU. A renormalization of the nominal 
output for the MLC-160 to a depth of 5 cm was made and the obtained value of 0.872 
Gy/100 MU differs from that of m3 in just 0.6%. The depth dose profiles were also 
compared for the common field sizes: 3×3 cm2, 6×6 cm2, 8×8 cm2 and 10×10 cm2. The 
obtained depth dose profiles coincided within less than 1%, with larger differences for 
smaller fields, mainly at the buildup region. 
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Figure 6.3 a) and b) presents the depth dose profiles obtained using field sizes 
of 3×3 mcm2 and 8×8 cm2 for the m3 and MLC-160 collimator systems. 
 
a)  
b)  
Figure 6.3 – Depth dose profiles of different field sizes for both collimator systems: a) 3×3 cm2; b) 8×8 
cm2. 
 
Based on the previous comparisons, we have assumed that the two dosimetric 
machines could be used for the proposed planning study.  
6.2.4 | Treatment planning  
Treatment planning is locally conducted using iPlan treatment planning system, 
version 4.5 from BrainLAB. Contrast enhanced magnetic resonance (MR) images of 
each patient are co-registered with planning computed tomography (CT) images 
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acquired in a big-bore CT simulator (Siemens Sensation Open). A head ring frame 
fixation system and the corresponding CT-localizer are used to enable the required 
stereotactic transformation performed at the planning workstation. The 
neuroradiologist approves the image fusion and delineates the gross tumour volume 
(GTV) and the relevant organs at risk (OARs) on the MR images. Subsequently, the 
planning target volume (PTV) is defined as the GTV plus an isotropic margin of 1mm 
incorporating the clinical target volume (CTV) and accounting for setup errors and 
other possible isocenter localizing uncertainties.  
For the present study, reference plans were created for m3. The plans used for 
treatment have not been used to prevent planner skills dependence. All clinical cases 
were re-planned with both MLCs using exactly the same treatment planning 
parameters, such as the isocenter location, the number of noncoplanar conformal arcs, 
the MLC margin, the gantry start and stop angles, the collimator and table rotation 
angles for each arc, and the prescription dose.  
Treatment plans were computed using a pencil beam algorithm for a 6 MV 
photon beam energy. A dose resolution of 1 mm was set. The adaptive grid option was 
used for the calculation of the dose matrix. In this option the dose grid size is 
automatically adapted to the volume of small structures guaranteeing at least 10 voxels 
for dose computation in all directions.  
6.2.5 | Plan quality evaluation parameters 
Target Coverage (TC) [11], Conformation Number (CN) [12], Conformity 
Index (CI) [11], Conformity/Gradient Index (CGI) [13] and the volume of normal tissue 
receiving at least 100% of the prescription dose (VNormPI,) were used to compare the 
treatment plans. The dose-volume indices have been reviewed in a former paper [14]. 
PTV dose-volume-histogram (DVH) parameters including minimum dose and 
maximum dose were computed and recorded. DVHs for the critical structures were 
compared in terms of the dose received by 0.1 cm3 of brainstem (D0.1cm
3) as well as the 
volume of critical organ that receives more than its tolerance dose and more than the 
prescribed dose. [10]. 
a) Improvement ratio  
A ratio to evaluate the improvement in each dose-volume index and the 
minimum and maximum dose to PTV between the two rival plans (a plan obtained with 
the m3 vs a plan obtained with the MLC-160) was defined as:  
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Improvement ratio (IR) (%)  =  
𝐼𝑛𝑑𝑒𝑥𝑀𝐿𝐶−160 − 𝐼𝑛𝑑𝑒𝑥𝑚3
𝐼𝑛𝑑𝑒𝑥𝑚3
× 100(%) 6.1 
 
For the dose-volume indices and the minimum dose to PTV a positive 
improvement ratio means that MLC-160 would performed better than m3 in terms of 
the corresponding index. When the maximum dose to PTV is evaluated, a positive 
improvement ratio means that the MLC-160 would contribute to a more heterogeneous 
dose distribution, what means a lower performance of MLC-160 vs. m3. 
6.2.6 | Statistical Analysis  
Statistical analysis was carried out using MATLAB version R2014a. The 
Wilcoxon signed rank test for paired samples was performed to assess differences 
between plans, with a p-value < 0.05 defining statistical significance. 
 
6.3 | Results 
6.3.1 | PTV coverage, Dose conformity and Conformity/ 
Gradient index 
The dosimetric indices and their improvement ratios according to the MLC leaf 
width (MLC-160 vs. m3) for the four groups of clinical cases are summarized in Table 
6.2. The Wilcoxon signed rank tests the null hypothesis which is that the median 
difference between pairs of observations is zero. Therefore, the p-value column in the 
table exhibits the probability of rejecting the null hypothesis (if p < 0.05 the indices are 
statistically different and the improvement ratio is real, either positive or negative). 
Also the median values of each evaluated parameter were included in Table 6.2. 
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Table 6.2 – Average quality indices and corresponding improvement ratios (± of MLC-160 versus 
m3. Median values are shown in parenthesis. 
Group Index m3 MLC-160 IR (%) p-value 
I 
(n=36) 
TC 
0.98 ± 0.01 
(0.98) 
0.98 ± 0.01 
(0.97) 
-0.09 ± 0.54 0.279 
CI 
0.72 ± 0.04 
(0.72) 
0.65 ± 0.04 
(0.65) 
-8.70 ± 4.78 1.68e-07 
CN 
0.70 ± 0.04 
(0.70) 
0.64 ± 0.04 
(0.64) 
-8.79 ± 4.69 1.68e-07 
CGI 
80.09 ± 2.36 
(79.83) 
77.23 ± 2.09 
(77.07) 
-3.55 ± 1.61 1.68e-07 
II 
(n=16) 
TC 
0.98 ± 0.01 
(0.98) 
0.98 ± 0.01 
(0.98) 
-0.11 ± 0.46 0.234 
CI 
0.73 ± 0.03 
(0.72) 
0.70 ± 0.03 
(0.71) 
-4.21 ± 3.38 0.001 
CN 
0.72 ± 0.03 
(0.71) 
0.69 ± 0.03 
(0.69) 
-4.32 ± 3.38 0.001 
CGI 
80.87 ± 2.35 
(81.09) 
79.91 ± 2.16 
(79.95) 
-1.18 ± 0.78 6.43e-04 
III 
(n=15) 
TC 
0.95 ± 0.07 
(0.97) 
0.94 ± 0.08 
(0.97) 
-0.81 ± 1.99 0.169 
CI 
0.70 ± 0.10 
(0.69) 
0.66 ± 0.10 
(0.65) 
-6.12 ± 7.43 0.003 
CN 
0.66 ± 0.07 
(0.67) 
0.62 ± 0.07 
(0.61) 
-6.84 ± 7.95 0.003 
CGI 
81.33 ± 9.93 
(80.45) 
78.87 ± 10.22 
(78.69) 
-3.05 ± 3.59 0.002 
IV 
(n=23) 
TC 
0.98 ± 0.08 
(0.98) 
0.97 ± 0.01 
(0.97) 
-0.91 ± 1.19 4.83e-04 
CI 
0.66 ± 0.08 
(0.67) 
0.59 ± 0.10 
(0.62) 
-11.11 ± 7.15 2.70e-05 
CN 
0.64 ± 0.08 
(0.66) 
0.57 ± 0.10 
(0.59) 
-11.91 ± 7.30 2.70e-05 
CGI 
75.90 ± 4.99 
(77.04) 
73.70 ± 5.75 
(75.79) 
-2.95 ± 2.57 3.09e-05 
 
a) Target Coverage  
An identical PTV coverage was achieved using the MLC-160 and the m3 for 
groups I, II and III (p>0.05). For group IV despite that the differences were statistically 
significant, the improvement ratio is negative and modest being on average less than 
1% (-0.91 ± 1.19%). This means that the MLC-160 would cover the targets just a little 
bit less, to 97% on average, instead of the 98% level achieved by the m3, for this type 
of irregular lesions as meningiomas. 
b) Conformity 
CI and CN indices indicate unequivocal statistically significant differences 
between m3 and MLC-160 for all groups in terms of dose conformity. Differences were 
higher for lesions with smaller volume (≤ 0.5 cm3, group I) or irregular shaped lesions 
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(group IV). When using the MLC-160, dose conformity deteriorated, on average, by 
around 9% for group I, 4% for group II, 6-7% for group III and 11-12% for group IV.  
c) Conformity/Gradient Index 
Regarding CGI improvement ratios were shown to be negative and of around 
3% for groups I, III and IV and just of around 1% for group II, indicating the lower 
performance of the MLC-160. 
6.3.2 | Minimum and Maximum target doses  
Minimum and maximum doses to the PTV are shown in Table 6.3. 
 
Table 6.3 – Average values of minimum and maximum doses (±1) to the PTV and corresponding 
improvement ratios for MLC-160 vs. m3. Median values are shown in parenthesis 
Group DPTV (%) m3 MLC-160 IR (%) p-value 
I 
(n=36) 
Dmin 
0.98 ± 0.01 
(0.98) 
0.97 ± 0.01 
(0.97) 
-0.69 ± 1.10 3.06e-04 
Dmax 
1.04 ± 0.01 
(1.04) 
1.04 ± 0.01 
(1.04) 
0.01 ± 0.53 0.694 
II 
(n=16) 
Dmin 
0.97 ± 0.01 
(0.97) 
0.96 ± 0.02 
(0.97) 
-0.41 ± 1.54 0.315 
Dmax 
1.08 ± 0.02 
(1.08) 
1.08 ± 0.02 
(1.07) 
-0.02 ± 0.54 0.275 
III 
(n=15) 
Dmin 
0.86 ± 0.14 
(0.90) 
0.85 ± 0.12 
(0.89) 
-0.39 ± 11.98 0.489 
Dmax 
1.13 ± 0.08 
(1.09) 
1.13 ± 0.07 
(1.11) 
-0.30 ± 2.63 0.946 
IV 
(n=23) 
Dmin 
0.92 ± 0.08 
(0.94) 
0.88 ± 0.08 
(0.90) 
-3.58 ± 4.43 4.69e-04 
Dmax 
1.12 ± 0.06 
(1.09) 
1.12 ± 0.07 
(1.09) 
0.75 ± 3.13 0.153 
 
No statistically significant differences were found between m3 and MLC-160 
for all groups, in terms of maximum dose to the PTV. Differences in terms of minimum 
dose were statistically significant for groups I and IV, with negative improvement 
ratios, which means that for lesions close to OARs and/or irregularly shaped, the MLC-
160 would lead to higher underdosages of the PTV. 
6.3.3 | Dose to critical structures 
For group III and group IV brainstem sparing was studied. Group III includes 
15 clinical cases of brain metastases located near the brainstem. Group IV includes 23 
clinical cases of meningiomas. Meningiomas appeared in any brain location, including 
at close proximity to brainstem, optical nerves or chiasm. For this group, in 14 cases 
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the lesion was located near the brainstem. In just two cases the chiasm and optic nerves 
were the considered OARs. Therefore, the brainstem was taken as the more relevant 
OAR to be reported for groups III and IV.  
The dose received by 0.1 cm3 of brainstem (D0.1cm
3) the volume of brainstem 
that received at least 12Gy and the volume of brainstem that received at least the 
prescription isodose are summarized in Table 6.4. 
 
Table 6.4 – Brainstem sparing average values (±1) for both collimators. Median values are shown in 
parenthesis. 
Group Parameter  m3 MLC-160 p-value 
III 
(n=16) 
D0.1cm3 (Gy)  
12.74 ± 1.55 
(12.85) 
13.61 ± 1.232 
(13.17) 
0.015 
V ≥ 12Gy (cm3)  
0.56 ± 1.03 
(0.21) 
0.71 ± 0.95 
(0.46) 
0.003 
V ≥ pi (cm3)  
0.37 ± 1.04 
(0.01) 
0.42 ± 0.98 
(0.02) 
0.065 
IV 
(n=14) 
D0.1cm3 (Gy)  
12.54 ± 1.93 
(13.42) 
13.14 ± 1.95 
(13.57) 
0.008 
V ≥ 12Gy (cm3)  
0.29 ± 0.25 
(0.32) 
0.53 ± 0.39 
(0.50) 
9.77e-04 
V ≥ pi (cm3)  
0.08 ± 0.08 
(0.07) 
0.23 ± 0.20 
(0.22) 
0.002 
 
Figure 6.4 a) and b) displays D0.1cm
3 received by brainstem for all clinical cases 
included in group III and for the clinical cases of group IV where the PTV is located at 
close proximity to the brainstem (n=14), using the m3 and the MLC-160, respectively. 
 
a)   b)  
Figure 6.4 – Dose received by 0.1 cm3 of brainstem for a) Group III (metastases close to the brainstem) 
b) Group IV (meningiomas located close to the brainstem) obtained using the m3 and the MLC-160. 
The dashed line represents the brainstem tolerance dose, 12 Gy. 
 
A quantitative evidence of improved brainstem sparing for the m3 over the 
MLC-160 is shown. The MLC-160 contributed on average for an increase in the dose 
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received by 0.1 cm3 of brainstem of around 1 Gy. When the MLC-160 was used, also 
the volume of brainstem that received at least its tolerance dose (V ≥ 12Gy) is on 
average, 1.83 times greater than the volume that received the same dose when the m3 
was used for group IV. Also for group III this difference is statistically significant but 
smaller (overdosed brainstem volume 1.27 times greater with MLC-160). The volume 
of brainstem that received at least the prescribed isodose is on average larger for the 
MLC-160 in both groups. Although being almost three times greater in group IV, the 
absolute volume of brainstem receiving at least the prescription dose is reduced, not 
surpassing 0.23 cm3, on average.  
6.3.4 | Dose to normal tissue 
The absolute volume of normal brain tissue irradiated to at least the prescribed 
dose for all lesions is summarized in Table 6.5. 
 
Table 6.5 – Average absolute volume (±1) of normal tissue irradiated to at least 100% of the 
prescribed dose, VNormPI. Median values are shown in parenthesis. The fourth and fifth columns are 
respectively the difference in volume for the two MLCs and this volume in percentage to the PTV 
volume. 
Group 
m3 
(cm3) 
MLC-160  
(cm3) 
Δ(MLC_160 - m3)   
(cm3) 
𝚫(𝐌𝐋𝐂_𝟏𝟔𝟎 − 𝐦𝟑)
𝑽𝑷𝑻𝑽
 (%) p-value 
I 
0.12 ± 0.06 
(0.10) 
0.16 ± 0.07 
(0.12) 
0.04 13.24 ± 7.93 1.68e-07 
II 
1.15 ± 0.83 
(0.99) 
1.35 ± 0.95 
(1.11) 
0.20 5.89 ± 4.76 0.001 
III 
1.53 ± 1.12 
(1.54) 
1.90 ± 1.57 
(1.34) 
0.37 9.29 ± 12.28 0.004 
IV 
2.02 ± 1.72 
(1.93) 
2.85 ± 2.79 
(2.28) 
0.83 20.18 ±16.93 4.01e-05 
 
For all lesion groups there was a statistical significant difference (p<0.05).  
According to the types of target, the differences for both MLCs in terms of 
VNorm100% relatively to the VPTV ranged, on average, from around 6% in group II to 
around 20% in group IV. It is important to evaluate both absolute and relative volumes 
as, for instance, in group I, the volumetric difference between the two MLCs is just 
0.04 cm3 but this small volume represents already more than 13% of the average 
volume of the metastases in this group. Therefore for group I, III and IV the MLC-160 
would lead to higher irradiation of the normal tissue. 
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6.4 | Discussion 
Four groups of clinical cases were created to evaluate  the eventual quality loss 
in treatment plans if the mMLC of BrainLab (3 mm minimum leaf width – m3) 
presently used for SRS was replaced by an integrated MLC with 5.0 mm leaf width, the 
Siemens 160 Multileaf Collimator (MLC-160). Plan comparisons included the use of 
dose-volume data, volumes of normal adjacent tissue and irradiated critical structures, 
as well as indices to evaluate target coverage and dose conformity. 
The plan quality differences mainly result from the different leaf widths and 
from the impossibility of the MLC-160 leafs to dynamically move along the irradiation 
arcs according to the beam’s eye view. Also other factors such as the leaves 
transmission and leakage are different in both machines and influence the evaluated 
dosimetric parameters. 
The same planner has done all the plans for the present study and has tried her 
best to achieve the best possible plan for each clinical case with the two MLC systems, 
without any time pressure. The average difference between the planning time for the 
worse cases for the two MLC systems was estimated in around 40 minutes, in favour 
of m3.  
The results demonstrated that identical PTV coverage would be achieved using 
either the m3 or the MLC-160. Regarding CGIg, dose falloff outside the target was not 
significantly different for m3 and MLC-160, so the observed statistically significant 
difference in terms of CGI index was due to a poorer conformity provided by the MLC-
160, which is in accordance with what CN and CI indices values revealed. 
Concerning the maximum dose received by the PTV, the differences between 
the two MLC systems were not statistically significant so the dose homogeneity would 
not change with the introduction of the MLC-160 in the clinical practice. Significant 
statistical differences were found in terms of the minimum dose to the PTV for groups 
I (lesions ≤ 0.5 cm3) and IV (meningiomas). However, the improvement ratio for small 
metastases (≤ 0.5 cm3) was just -0.69% ± 1.10% which may not be clinically significant 
as for both MLCs the achieved minimum doses were above 95% of the prescribed dose. 
The minimum dose to the PTV in groups III and IV were always lower than 95% of the 
prescribed dose which means that close to OARs with lower tolerance doses than the 
prescribed dose, a compromise is usually established between proper PTV coverage 
and critical organ sparing trying to reduce toxicity. In these cases, the statistical 
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significant difference obtained for group IV between the minimum dose to the PTV 
with the m3 and the MLC-160 may have significant clinical impact. We can preview 
that the use of the MLC-160 would probably lead to more significant underdosages of 
irregular lesions close to organs at risk. 
Dose conformity was consistently better for the m3 plans that for MLC-160 
plans. The effect of target volume was compared for groups I and II. As expected, the 
dose conformity was higher for larger lesions. Although the conformity of the MLC-
160 plans was systematically poorer than that of the m3 plans, both CN and CI indices 
were, on average, greater than 0.6 which means that the MLC-160 treatment plans 
would be clinically acceptable as conformal. 
 Group III included brain metastases located at close proximity or within the 
brainstem. Therefore organ at risk sparing was a limiting factor that had to be taken into 
account during planning. Good conformity, with average and median conformity 
indices above 0.6, could be achieved with both MLCs as was shown in Table 6.2. 
However the conformity index would assume poorer values in 6-7% if the m3 was 
replaced by the MLC-160.  
The fourth group was formed by meningiomas which are typically irregular 
lesions. This group had the poorer conformity. With the MLC-160 the plans could not 
achieve acceptable conformity, on average. The defined improvement ration assumed 
the highest negative average values (around -12%), meaning that the plan conformity 
would suffer important decrease with the MLC replacement.  
We believe that the higher differences between the two MLC systems in terms 
of dose conformity for group IV relatively to group III were due to the meningioma 
irregular shapes. For irregular shape lesions, the static conformal irradiation would 
represent the highest limitation in the scenario of MLC replacement.  
The volume of normal tissue irradiated to at least the prescription dose was 
consistently greater for plans using the MLC-160 over the m3 for all groups but in 
higher amount for groups I, III and IV. Table 6.4 shows that the MLC-160 would also 
contribute for a higher organ at risk affectation. For clinical cases of meningioma or 
metastases close to organs at risk, therapeutic dose and lesions location could 
compromise the brainstem tolerance dose, as D0.1cm
3 values showed. 
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6.5 | Conclusions 
If a tertiary 3 mm micro-multileaf collimator of BrainLab presently used for 
stereotactic radiosurgery was replaced on the Siemens Avant-Garde linear accelerator 
by an integrated Siemens 160 MLC with 5 mm leaf width, organs at risk sparing and 
dose conformity of lesions located at close proximity to organs at risk and highly 
irregular shaped lesions would be the main losses in terms of plan quality. Another 
important result from the study and still linked with the previously referred ones was 
that the minimum dose to the PTV would significantly be reduced for the larger width 
leaf MLC, what would contribute to poorer clinical outcome or higher toxicity as a 
tradeoff.  
The main reason for the observed results was not just the larger leaf width of 
MLC-160 but the fact that this system integration in the local linear accelerator would 
have the limitation of not enabling dynamic conformal arcs for the SRS technique.  
As a consequence, treatment planning using the MLC-160 has been a 
cumbersome and time consuming task for all considered groups of lesions, mainly for 
irregular shaped lesions and lesions located near eloquent areas. The planning time has 
easily been doubled when compared to the planning time using the m3 collimator which 
is not an irrelevant issue when real treatment cases are to be considered in SRS where 
the treatment planning must be done on the same day as the treatment.  
Considering all clinical studied cases, 5.56% (2/36) of the cases included in 
group I, 33% (5/15) in group III and 35% (8/23) in group IV would not be clinically 
acceptable if the intended replacement of the collimation system would take place. 
Therefore the eventual MLC replacement would not represent a beneficial option 
considering the local SRS treatment experience.  
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The objective of speeding up the radiosurgery treatment planning phase was 
fully accomplished. The first study of this project involved acoustic neurinoma clinical 
cases and the development of a corresponding specific template. Applying the proposed 
specific template for acoustic neurinoma, with further adjustment of the mMLC for just 
two of the six dynamic arcs used for treatment, plan acceptance quality criteria was 
achieved. This represented a considerable reduction – to around 1/3 – of the treatment 
planning time.  
The acquired know-how about the treatment planning system and associated 
tools was afterwords applied to major group of SRS clinical cases – brain metastases. 
Specific templates for different metastatic lesions locations with further adjustment in 
just three arcs of the 6/7 dynamic arcs used for treatment allow to achieve treatment 
plans compliance with the local plan acceptability criteria. This contributed for a 
reduction of the treatment planning time to around 1/2-1/3 without compromising the 
plan quality. A useful graphical tool was also developed to help the quick choice of the 
applicable metastase template. This tool and the developed templates are presently used 
in clinical routine.  
The casuistic of all brain metastases treated with linear accelerator based 
stereotactic radiosurgery was reported and the outcome of SRS was evaluated for 250 
metastases in 168 patients treated between March 2008 and December 2014. This study 
enabled the reporting of the full database of brain metastases treated at IPOCFG. The 
subsequent statistical study revealed a median overall survival of 9 months from the 
date of the SRS for a follow-up time of 24 months. Statistical analysis showed that 
patient’s age and primary tumour location were significant predictive factors for 
survival, whereas the number of brain metastases was not shown to be a significant 
factor. Local control was achieved in 85.2% of the evaluated brain metastases. No 
significant factors were associated with the local tumour progression.  
Finally, the last study of the project concerned the management decision on 
dispensing the use of m3 in SRS by replacing it with an integrated multileaf collimator 
with 5 mm leaf width (MLC-160). The results of the presented work showed that the 
MLC replacement would imply important drawbacks in terms of plan quality for a 
significant percentage of the clinical cases treated at IPOCFG. Considering all the 
studied cases, organs at risk sparing and dose conformity of lesions located at close 
proximity to organs at risk and highly irregular shaped lesions would be less effective 
if the intended replacement of the collimation system would take place.
  
  
 
